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RÉSUMÉ 
Malgré les mesures récentes des organismes de réglementation, il y a encore des lacunes dans 
la mise en œuvre de formulations adaptées à l'âge à l’intention de la population pédiatrique. Les 
différences au sein de cette population, conjuguées à la non-adhésion thérapeutique due au mauvais 
goût des médicaments, présentent de grands défis pour la formulation de médicaments pris par voie 
orale. Des formulations orales solides souples, comme les microsphères, ont été proposées comme 
solutions de rechange aux formulations déjà commercialisées, comme les comprimés ou les formes 
posologiques orales liquides. Les microsphères sont des systèmes matriciels dans lesquels le principe 
actif (PA) est dispersé. Le PA est donc subdivisé en plusieurs petites unités posologiques. De plus, les 
microsphères peuvent être enrobées afin de masquer le goût. La stratégie consiste à appliquer une 
barrière protectrice à la microsphère qui empêchera la libération du médicament dans la cavité buccale, 
tout en maintenant une libération immédiate dès que le produit médicamenteux atteint le site 
d’absorption, pour ainsi obtenir un profil neutre sur le plan du goût sans affecter la biodisponibilité du 
PA. Les lits d’air fluidisé avec : Wurster sont utilisés depuis plusieurs années dans l’industrie 
pharmaceutique pour enrober les petites particules, car ils produisent des particules uniformément 
enrobés. 
La nécessité d’acquérir une meilleure compréhension des procédés conventionnels utilisés dans 
l’industrie pharmaceutique est connue. Les organismes de réglementation favorisent l’utilisation des 
principes de qualité par la conception, ainsi que des nouvelles technologies, comme les outils de la 
technologie d’analyse des procédés (PAT), dans le but d’élaborer une stratégie pour transformer un 
procédé de fabrication qui se rapproche davantage d’une forme d’art en procédé basé sur des données 
scientifiques. La présente thèse porte spécifiquement sur cette question et plus particulièrement sur une 
meilleure compréhension de la relation entre la formulation de la solution d’enrobage et le procédé 
d’enrobage pour la dissolution du PA. 
Dans le cadre de ces travaux, un plan d’expérience D-optimal couplé à la mise en œuvre de 
trois outils PAT en ligne a permis d’identifier les paramètres critiques du procédé et les attributs 
critiques du matériau (formulation de la solution d’enrobage) qui influencent la libération in-vitro du 
PA au pH buccal. Le niveau de l’enrobage, le niveau de plastifiant, le débit, la température du lit et le 
durcissement sont les paramètres critiques identifiés pour une formation complète du film. La criticité 
de la morphologie de l’enrobage sur la dissolution dans la salive simulée est également démontrée. La 
performance en ligne de la spectroscopie Raman, de la spectroscopie proche infrarouge et de la mesure 
de la réflectance du faisceau focalisé, ainsi que les données du procédé et les attributs des matières 
premières sont évalués et comparés pour faire le suivi du procédé d’enrobage des microsphères. En 
recourant à une analyse multiblock partial least squares, il est démontré que la spectroscopie Raman a 
une performance supérieure pour assurer le suivi du procédé et obtenir ainsi un enrobage constant pour 
la membrane barrière à couche mince, essentielle à l'observance du patient. 
Mots clefs : enrobage, lit d’air fluidisé avec Wurster, masquage du goût, microsphères, 
technologie d’analyse des procédés 
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ABSTRACT 
Despite recent incentives provided by regulatory agencies there is still a gap in the 
implementation of age-appropriate formulations for the pediatric population. The differences within 
this population, coupled with the non-compliance due to poor taste, present great challenges for oral 
drug formulation. Flexible solid oral formulations, such as microspheres, have been proposed as 
alternatives to existing marketed formulations such as tablets or liquid oral dosage forms. Microspheres 
are matrix systems where the Active Pharmaceutical Ingredient (API) is dispersed. The API is thus 
subdivided into a plurality of small dosage units. Additionally, microspheres can be coated as a 
strategy to achieve taste masking. It consists in applying a protective barrier to the microsphere that 
will prevent the release of drug in the oral cavity, while maintaining an immediate release once the 
drug product reaches the absorption site, thereby achieving a taste neutral profile without adversely 
affect the bioavailabity of the API. To coat small particles Wurster fluid bed coaters have been used for 
many years in the pharmaceutical industry, as they produce uniformly coated particles. 
There is a recognized need to better understand conventional processes used within the 
pharmaceutical industry. The regulatory agencies have encouraged the employment of quality by 
design principles, together with new technologies, such as Process Analytical Technology (PAT) tools, 
with the aim of developing a strategy to transform, what is generally considered an art form, into sound 
science based processes. This thesis specifically concerns this issue by focusing on better 
understanding the relation between both coating formulation and coating process to dissolution of the 
API. 
In this work, a D-optimal design coupled with the implementation of three in-line PAT tools 
helped identify the critical process parameters and critical material attributes (coating formulation) 
influencing in-vitro API release at mouth pH. Coating level, plasticizer level, spray rate and product 
bed temperature and curing are the identified critical parameters for a complete film formation. The 
criticality of coating morphology on the dissolution in simulated saliva is also demonstrated. The in-
line performance of Raman spectroscopy, near infrared spectroscopy and focused beam reflectance 
measurement, together with process data and raw material attribute is evaluated and compared to 
monitor the microsphere coating process. By resorting to multiblock partial least squares it is shown 
that Raman has superior performance to ensure consistent coating performance for thin film barrier 
membrane, essential to patient compliance. 
Key words: Coating, fluid bed with Wurster insert, taste masking, microspheres, process 
analytical technology 
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CHAPTER 1 INTRODUCTION 
1.1 Context and motivation 
There are different challenges concerning the development of pediatric drug formulations, for 
example, an important factor (that is often overlooked), is the heterogeneity within the pediatric 
population[1] — it includes well defined sub-populations (pre-term newborns, newborns, infants and 
toddlers, children and adolescence) that will exhibit different responses not only for the active 
substance but also to the excipients added[2].  The Safety and Toxicity of Excipients for Pediatrics 
(STEP) database has been created to address the need to capture, manage and maintain valid safety, 
tolerability and toxicity of excipients used world-wide for pediatric drug formulation[3]. 
Nonetheless, it is frequent for physicians to prescribe medication that has not been approved 
for use in pediatric patients[4].  Pediatric labeling is a relatively small market (less than 10% of the 
pharmaceutical market[4]), research is expensive and complicated, and there are numerous practical 
and moral issues associated with clinical trials for pediatric studies. As a consequence, most of the 
time, medication is prescribed for pediatric use without taking into consideration neither the 
differences in pharmacokinetics and pharmacodynamics between pediatric patients and adults, nor 
disease states[5].  
The adopted strategy has been to encourage pediatric drug studies through regulatory 
requirements and financial incentives. In order to promote the required synergy for the development 
and availability of age appropriate medicines for children, pediatric regulatory environment have been 
created all over the world. In the United States of America, the Best Pharmaceuticals for Children Act 
and the Pediatric Research Equity Act were created. The Pediatric Research Equity Act can make it 
mandatory to perform safety testing in all relevant pediatric subpopulations for a drug submitted in a 
new drug or, new biologics applications for adult indication if the Food and Drug Administration 
(FDA) so requires[6]. The Best Pharmaceuticals for Children Act grants new products, that complete 
pediatric testing, a 6-month patent extension (regardless of the approval for pediatric patients)[6]. 
Companies that test orphaned drugs are granted a two-year extension of the standard ten-year market 
exclusivity and furthermore, there is a new authorization category, the Pediatric Use Marketing 
Authorization, encouraging pediatric testing of drugs whose patent exclusivity has expired. Such 
testing may result in an additional ten-year market exclusivity.[7] In the European Union, it is the 
Pediatric Regulation stimulating the new trials and formulations[8]. A list of high priority medicines 
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has been released in an attempt to guide the research where it is needed, focusing on off-label drugs 
and gaps in pediatric data [9]. 
Within the currently prescribed medication, lack of adherence by the pediatric population has 
long been acknowledged as a problem[10]. DiMatteo[11] estimated that the yearly cost associated with 
non-adherence was as high as 300 billion US dollars a year. There are a multitude of factors 
contributing to the lack of compliance and despite the effort that has been made to understand the 
reasons behind drug adherence problems in pediatrics, many questions still linger [10]. Despite this 
fact, some key factors have been recognized and they include not only socio-economic circumstances 
and adverse effects of the medication, but also attributes of the dosage form itself, such as palatability 
[10], [12] and dosage form. Taste was indicated as the greatest barrier to completing treatment by more 
than 90% of pediatricians[13], as drugs often exhibit an unpleasant bitter taste, frequently perceived as 
a “bad taste”[13]–[15]. 
The oral route is still the preferred route of administration in children[2], [14], [16], [17]. 
Liquid oral pediatric dosage forms (oral suspensions and solutions) are the most common formulations 
found in the market. Usually, to disguise the bitter taste, high-intensity sweeteners, flavors and acids 
are added to the formulation[13], [14]. The addition of these excipients might help reduce the 
bitterness, but it will not eliminate it[14]. Liquid preparations have identified shortcomings regarding 
palatability, stability (chemical, physical or microbiological) and transport to lower-income 
countries[17]. One needs to take into account that the lack of access to medicines is mostly in children 
living in developing countries[2], as it has been highlighted by the WHO initiative: “Make Medicines 
Child Size”. Consequently, there is a growing preference to adopt solid oral dosage formulations. Not 
to say that these dosage forms are without their challenges, such as chocking and chewing risks, but 
they have the potential to overcome the issues of traditional liquid preparations. 
Many solid oral dosage forms have the advantage of masking or encapsulating the taste. 
However, inability to swallow tablets and capsules is a common problem within the pediatric 
population, as such, these dosage forms are usually perceived as being appropriate for older 
children[18]. The ability to swallow varies greatly within the pediatric population. Chewables and 
(oro-) dispersable tablets are easier to swallow, but taste masking is still an issue that needs to be 
addressed[14].  
As first reported by Sam et al.[19] the ideal pediatric formulation will have to be an integrated 
approach where formulation, manufacturing process, packaging and administration device meet the 
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needs of the patients, caregivers, healthcare providers and manufacturers[20]. Being that the final oral 
dosage form should be flexible, convenient to handle, have acceptable taste, minimal administration 
frequency, adequate bioavailability, minimal number of excipients, have a robust manufacturing 
process, be stable, be commercially viable at an acceptable cost for the patient and payers and finally 
be easily transported and stored[20].  
This view is well aligned with the concept of Quality by Design (QbD), as it is defined in the 
ICH Q8 “a systematic approach to development that begins with predefined objectives and emphasis 
product and process understanding and process control, based on sound science and quality risk 
management”[21]. Process analytical technology (PAT) is under the QbD framework blanket as it can 
act as a facilitator to the process of knowledge transfer from a research and development space to 
production[22]. PAT is commonly used to refer to the ability to monitor a process real-time, improve 
process understanding and control the quality of the manufactured product[23]. PAT has been 
established as a scientific approach to support innovation and development within the pharmaceutical 
industry[24] in order to ensure quality and consistency of the final product. In early stage process 
development, PAT applications focus on establishing a measuring system to help identify and 
understand relationships among critical formulation, process factors and critical quality attributes. This 
knowledge is then used to establish a robust control strategy during robust manufacturing to control 
and supervise the process. 
This work aims at developing fundamental knowledge of the parameters that affect the 
properties of the particle coating and at determining their impact on the Active Pharmaceutical 
Ingredient (API) release. 
1.2 Problem statement and definition 
Microspheres (Figure 1.1), as well as other multiparticulate systems, have been identified as a 
flexible dosage form that can be used as a platform technology [14], [17] for oral medicine requiring 
precise dose measurement. Platform technology is defined, in Annex 5 of the 46th WHO report on 
Specifications for Pharmaceutical Preparations, as a “technique, including formulation and related 
processes, which can be used to obtain different dosage forms, different strengths and/or accommodate 
different APIs”[2]. Microsphere drug delivery systems consist of a plurality of discrete small dosage 
units, each exhibiting some desired characteristic where the API is dispersed in a matrix[25]. 
Microspheres can be a starting point for the dosage form, offering the possibility of being further 
processed into a wide range of alternative pediatric drug delivery systems, providing the opportunity of 
4 CHAPTER 1 INTRODUCTION  
 
taste masking. The topic of microsphere manufacturing is further developed in sub-chapter 2.2.1 
Making microspheres. 
 
 
Figure 1.1 Melt spray congeal microspheres 
On the subject of the taste masking technologies, there are several strategies that can be 
adopted: modifying the drug molecule, modifying formulation pH, barrier approach, drug complexes, 
disguising bad taste or blocking taste receptor[14], [26]. It is important to mention that the barrier 
approach is the most widely used, accounting for 27% of patents and patent applications[26] in the 
field of taste masking technology in the period between 1997 and 2007. The barrier approach, in taste 
masking, consists of applying a coating (or barrier) to the core containing the API. This approach will 
prevent the API from going into solution while in the oral cavity. However, one must ensure the 
release of the drug afterwards (in the gastro-intestinal track) so that pharmacokinetics are not adversely 
affected[14]. 
As several factors influence the choice of coating to use, selection of the taste-masking coating 
needs to be done on a case-by-case scenario that takes into account the properties of the API, the dose 
level, the dosage form and the release profile among other factors. For taste masking purposes, the 
polymer should not allow the release of the API in the oral cavity, but it should allow the release of the 
drug in the expected absorption site (intestine or stomach)[27] in order not to hinder bioavailability of 
the drug. In the particular case of this work, the chosen solution was to study a reverse enteric polymer 
system, this is, using polymers that are insoluble at mouth pH, but soluble in gastric pH [27]. They are 
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cationic polymers with a defined number of tertiary amino groups, that dissolve under protonation in 
acidic media of pH 5.5[28] and below. The solubility pH-dependency should ensure an effective 
protection in the mouth and a quick release in the stomach. 
Kollicoat®Smartseal 30D is a novel aqueous dispersion developed specifically for taste-
masking applications and moisture protection for orally administered pharmaceutical products by 
BASF and Colorcon[29]. Kollicoat®Smartseal 30D has type IV (“excipient, colorant, flavor, essence, 
or material used in their preparation”[30]) and type V (“FDA accepted reference information” [30]) 
drug master files, a submission to the FDA that contains the chemistry, manufacturing and controls of  
a substance used for drug formulations, making Kollicoat®Smartseal 30D a strong candidate for future 
“new drug application” filings. Kollicoat®Smartseal 30D was chosen in this study because it is 
representative of the methacrylic acid polymer family that is commercially available on the market and 
no work was found in the literature that links coating formulation and process parameters to the 
dissolution performance of this coating. With a proper understanding of the impact of the critical 
process parameters (CPPs) and critical material attributes (CMAs) on the critical quality attributes 
(CQAs), effective taste masking of pediatric coated microspheres with Kollicoat®Smartseal 30D 
reverse enteric should be possible to achieve. This is assuming that: 
1. The bad taste is exclusively due to the API release in the mouth  
2. By coating the microspheres we eliminate the contact of the “bad-tasting” API with the 
taste buds, and thus the taste is no longer perceived. 
This work aims at answering one question: “How do the methacrylic acid coating formulation 
and processing conditions in the fluid bed with a Wurster insert, affect the quality of the taste masked 
melt-spray congeal microsphere’s coating?” 
1.3 Objectives 
The main objectives of this work are: 
 To develop further understanding of parameters that affect microspheres coating 
properties with a methacrylic acid-based aqueous dispersion (reverse enteric polymer 
blend) and to determine their impact on the API release profile at pH 6.2; 
 To develop a robust barrier membrane and barrier membrane manufacturing process 
to produce taste masked microspheres for pediatric use. This requires simultaneously 
studying coating formulation parameters such as, plasticizer concentration and solids’ 
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in suspension, and fluid bed coating with a Wurster insert unit operation process 
parameters: product bed temperature, air flow, spray rate, atomizing air pressure, coat 
weight gain and curing. In order to determine which are the CPPs and/ CMAs and 
their impact on the required CQAs:  
o Coating thickness – 4 to 20µm 
o Coating uniformity – non-porous film 
o Taste masking performance (neutral taste in the mouth), evaluated by the non-
dissolution of API in 0.05M Potassium Buffer at pH 6.2 
o API release in hydrochloric acid pH 1.2 
It is essential to select the PAT tool(s) that are able to monitor the above mention CQAs. The 
use of PAT tools will help monitor the coating process, and thus develop a systematic understanding of 
it. 
1.4 Original contributions 
The most relevant contributions of this work include: 
 Demonstrate the robustness of a methacrylic acid-based polymer coating membrane 
and process after curing. Within the chosen design space from the seven initial key 
variables, the remaining CPP and CMA is coating level, percentage of plasticizer, 
spray rate and temperature, with the curing being a crucial part of the process as it 
allows for a complete film formation and reduces overall variability within the batch.  
 Demonstrate that when studying coating performance, the microstructure of the 
coating is of great importance. Coating thickness helps explain the majority of the 
variation in coating performance. Nevertheless, coatings of the same thickness can 
sometimes display very difference taste masking performance. It is the microstructural 
differences within those coatings that help understand how the variations in 
formulation and process impact the dissolution performance. 
 Determine if Multiblock Partial Least Squares (MBPLS) can provide a visually 
simplistic way to compare different sources of information (or even combine them).  
The potential benefits of using near infrared (NIR) spectroscopy, Raman spectroscopy, 
focus beam reflectance measurement (FBRM), process data or raw material properties 
to predict taste masking performance of reverse enteric polymer applied to melt-spray 
congeal microspheres was investigated. It would not be feasible to integrate all these 
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tools in a control strategy in an industrial context, MBPLS was helpful demonstrating 
that, within the evaluated blocks of information and the current set-up, Raman 
outperformed the other sources of information. 
 Show how Raman could be potentially used to establish a control strategy for fluid bed 
coating: by demonstrating that variation in Raman signal correlates to the variations in 
product performance, showing that Raman can be used to monitor the coating process 
(beginning to end) and to identify process disruptions (such as spray rate changes). 
 Aid the development of platform manufacturing technologies that can produce high 
quality dosage forms for the pediatric population in a reliable and replicable manner. 
1.5 Thesis outline 
This thesis is organized into five main chapters that will follow the outline described below. 
This initial chapter (Chapter 1) is a small introduction that defines the framework, motivation 
and original contributions of the work developed.  
Chapter 2, consists on a literary review of the foundations and evolving perspective on taste 
masking, with special focus on coating, which is of central interest for this project. It covers the state of 
the art on some of the critical concepts used throughout this thesis, namely on the coating suspension 
formulation, Wurster coating process, QbD and multivariate data analysis.  
Chapter 3 and Chapter 4 detail the carried out research work. First the employment of QbD 
concepts/tools to define the critical process and formulation attributes for the taste masking 
performance. Showing how the in vitro performance of the coating, evaluated by dissolution testing at 
pH 6.2 is greatly influenced not only by thickness, but also by the microstructure of the coating. The 
second step was to demonstrate the usefulness of PAT tools to compute in-line prediction of the 
coating performance. Both chapters are based in submitted paper to peer-reviewed journals. For 
consistency purposes minor changes were made to both documents. 
Chapter 5 summarizes the main conclusions from the work and draws recommendations for 
future work. 
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CHAPTER 2 STATE OF THE ART 
2.1 Taste masking 
Since the European medical agency has included the palatability of the product as an 
acceptability criteria in its Guideline on Pharmaceutical Development of Medicines for Pediatric 
Use[31], there has been a lot of emphasis on taste masking to try and improve compliance among the 
pediatric population. 
The extent to which taste masking is required, is dependent on the physiochemical properties 
of the API, as well as its taste threshold[14]. In addition, measures to mask the taste of oral dosage 
forms must include degree of effectiveness, but also avoid negative effects over any sensory 
awareness[32], such as mucosa irritation, roughness in the mouth or hindered swallowing. 
The factors taken into account during the taste masking formulation development include: 
extent of the bitter taste of the API, number of excipients, dose load, drug particulate shape and size 
distribution, drug solubility and ionic characteristics, required disintegration and dissolution rate of the 
finished product, desired bioavailability, desired release profile, stability (shelf-life and in-use), 
required dosage form and commercial viability [20], [27]. There are generally four taste masking 
principles[15] modification of formulation and/or pH, solid dispersions, chemical or solubility 
modification and physical barrier. 
2.1.1 Modification of formulation and/or pH 
The most used principals in liquid formulations to mask bad-taste are: 1) modification of 
formulation, by adding sweeteners and flavors[13]–[15] or 2) modifying pH. It is known that children 
have a higher tolerance threshold to sweetness (compared to adults), which explains the generalized 
use of sweeteners in pediatric formulation. Liquid dosage forms also have intrinsic limitations, such as, 
stability issues, higher transportation costs and challenging controlled release. In order to maintain 
chemical stability of medication that is prone to hydrolysis, pH modification is a commonly used 
strategy in liquid formulations[13]. For bitter drugs with a low detection taste threshold, these 
modifications do not provide adequate means for taste masking[15]. The lack of controlled-release 
formulations results in the need to administer multiple dosages throughout the day[20]. 
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2.1.2 Solid dispersions 
Solid dispersions are characterized by having one or more APIs randomly distributed, or 
dispersed, in an inert solid carrier[15], [26], such as polymers, sugars, waxes or other suitable carrier 
agents[33]. The granules can be formed by either solidifying the molten mixture, as in spray 
congealing, melt granulation and hot melt extrusion. Reported drawbacks[15] of these technologies 
include their unsuitability for heat sensitive products. Taste masking by solid dispersion can also be 
achieved by precipitation followed by solvent evaporation. 
However, like in the case of modification of the formulation by adding sweeteners or pH, 
depending on the taste threshold of the API, taste masking is often incomplete. Frequently, these 
approaches require the addition of taste-modifying agents or further coating of the pellets produced by 
solid dispersion. 
2.1.3 Chemical or solubility modification 
Solubility modification is used to decrease the solubility of the drug in the mouth, the 
hypothesis is that if the drug does not dissolve in the mouth, then the perception of the drug’s bitter 
taste will also be reduced, or even eliminated. Although solubility modification is a simple process, its 
applicability is limited as it is only applicable to those drugs that have a pH-dependent solubility[15]. 
Developing a new molecule, that will still have the same pharmacokinetics but a different solubility, is 
a time consuming route. 
Another option for taste masking is inclusion complexation. In this application, the API is 
entrapped into the “cavity” of a complexing agent, this is to say the host molecule, thus forming a 
stable complex[33]. The most common used complexation agents are cyclodextrins[15]; theoretically 
they either enclose the drug to inhibit its interaction with the taste buds, or interact with the gatekeeper 
proteins of the taste buds (bitter blockers)[26] to block them. There is still limited understanding of the 
tasting mechanism and bitter blockers[14], a reason that justifies the unfeasibility of the latest approach 
for a commercial product for the time being. 
Ion exchange resins are crosslinked water-insoluble polymer carrying ionizable functional 
groups[34], that in turn can be either cationic or anionic[35]. The drug can be bound to the resin 
through weak ionic bonding, to an oppositely charged resin[26], so that dissociation of the drug-resin 
complex does not occur in the oral cavity[15]. Drug release from the resin depends on the properties of 
the resin itself and the ionic environment of the gastro intestinal tract[33]. The drug’s release involves 
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ion exchange between those ions present in the gastro intestinal tract and those of the drug attached to 
the resins[15], which can have a negative impact on the bioavailability of the drug[14].  
All in all, these approaches imply high development costs and lengthen timelines, with a 
variable success rate[14], which justifies the limited use of this technology for taste masking. In the 
period between 1997 and 2007 less than 5% of the total taste masking patents and patent applications 
focused on these technologies. 
2.1.4 Physical barrier 
A uniform physical barrier coated onto the API is the most efficient way of successfully 
providing a palatable oral dosage form. For this reason in the period between 1997 and 2007, coating 
(application of a physical barrier) accounted for 27% of the patents[26], making it the most commonly 
used technique of that decade[26]. 
The coating system can be classified accordingly to the type of coating material (molten or 
polymeric), coating solvent system (aqueous, organic or dry)[26] or by the coating technology. The 
discussion on coating material and formulation is made in sub-section 2.3 of this same document. Let 
us start by reviewing the available coating technologies.  
Dry coating is an alternative that has been progressively gaining attention, as wet coating 
methods have become less desirable due to environmental concerns over resulting waste streams and 
possible volatile organic compound emissions[36], as well as typically longer process times for 
aqueous coating systems[37] or even for moisture sensitive APIs. In dry particle coating, submicron-
sized guest particles are typically attached to micron-sized particles without using any solvents or 
binders[36]. Based on the above definition, it is reasonable to assess that the difference in particle size 
of the coating material and the core is a key parameter. There has been some work reported in the field 
of taste masking for tablets[37]–[41], and more recently on pellets with the purpose of taste 
masking[42], [43]. Capece et al.[44] have used a solventless dry coating process that makes use of 
high-intensity vibrations (laboratory resonance acoustic mixer, LabRAM), in order to avoid the use of 
plasticizers, binders and heat treatments to coat APIs. 
The work to be developed will focus on fluid bed coating, as it is a well-established technology 
in the pharmaceutical industry due to its versatility[15]. In fluidized beds, the coating solution is 
usually sprayed onto particles by a two-fluid nozzle located at the top, bottom or horizontally in 
relation to the product bed[45]. Top spray coaters have been reported to present high porosity coatings 
and difficulties in achieving uniform film application[27]. Tangential coaters, also sometimes called, 
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rotor coating systems[46], consist of a disk rotating in the fluidizing chamber and a spray placed 
horizontally in the reactor. Centrifugal force causes the product to move toward the wall of the 
chamber, air velocity through the gap provides acceleration upward, and gravity and turbulent eddies 
force the product inward and toward the disc center[46].The combination of the rotation and the air 
flow provides specific properties, such as higher spherical shape and density to the resulting coated 
particles[47]. The main drawback of this technology is its applicability. Due to the high level of 
agitation in the reactor, it is not suited for coating materials that are crumbly or friable[48]. Given that 
Wurster coaters will be the focus of this work, sections 2.4 Fluid bed with Wurster coating will 
elaborate on the description of the system and the influence of several parameters.  
2.2 Multiparticulate drug delivery systems 
Multiparticulate drug delivery systems consist of a plurality of discrete small dosage units, 
meaning that a single dose of an API is subdivided into a multiplicity of small independent 
subunits[14], [16], each exhibiting some desired characteristic. Contrary to single-unit forms, which 
retain their structure in the digestive tract, multiparticulates will disperse in the gastro-intestinal track 
after administration[49]. Generally they are small easy to swallow spherical particles with diameters in 
the range of 0.05 (or smaller) to 2.00 mm[16], [49]; they comprise microcapsules, microspheres and 
pellets[20]. 
To deliver the total dose, the small discrete particles are combined into a single dosage form, 
that can range from ‘sprinkles’ to (less commonly) compressed tablets[50]. A numerous combinations 
of dosage form and administration options can be used[14]. This flexibility of dosage form and dosage 
administration gives multiparticulate systems a great advantage over single-unit systems (such as non-
disintegrating dosage forms). It allows for an easy adjustment of the strength of a dosage unit by 
simply changing the number of multiparticulates[14], [50]. It also allows for the combination of 
multiparticulates with different drug release rates to obtain the desired overall release profile[50], or to 
obtain the same result by layering different drugs onto a starting core[14]. In allowing the development 
of sustained release solutions, multiparticulates can potentially reduce the burden of repeated 
administration by offering the opportunity to develop fixed-dose combination (where two or more 
drugs are combined in a single dosage form[51]). 
Failure of a drug delivery unit can be caused by a multitude of reasons. For example, it can be 
due to lack of disintegration of the unit or non-dissolution of the API, or by the early release of the 
API, the cause and definition of failure of a dosage form will depend on the end goal of the 
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formulation. Regardless, in multiparticulate systems, the API is divided into many subunits. Failure of 
a few units may not be as critical as the failure of a single-unit system[16]. Due to their small size, 
multiparticulates are less dependent on gastric emptying, because they can pass the pyloric sphincter 
easily[50], even when it is closed[16]. By enabling a good distribution along the gastrointestinal tract 
and improving absorption, multiparticulate systems reduce intra- and inter- subject variation in 
gastrointestinal time, plasma levels, bioavailability and reduce irritant effect that may be induced by 
single-units if lodged at a particular site for a prolonged period of time[50]. All in all, multiparticulate 
drug delivery systems have shown to give superior reproducible pharmacokinetic behavior in 
comparison to monolithic drug formulations[52]. 
The multiparticulate approach is not without some disadvantages, to name the two major ones: 
gritiness/mouthfeel and co-administration with food. Pour mouthfeel (gritiness) can make a 
formulation unacceptable to the patient. As for administrating the microspheres with food, it is a 
double edge sword. On the one hand it has been reported to have had helped improve organoleptic 
properties, on the other hand it might have an impact on drug’s bioavailability[14].  
Nevertheless, multiparticulates stand out as the flexible solid dosage form for pediatric use[53] 
with the great advantage of being suitable for taste masking by film coating, which will also help to 
improve patient’s compliance.  
2.2.1 Making microspheres 
Microspheres consist of multiparticulates system of a fairly homogeneous mixture of matrix 
and API[54]. They are not to be confused with microcapsules as they differ in morphology and internal 
structure (Figure 2.1). Microcapsules have at least one discrete domain of API (or more) and are 
reservoir systems[54]. 
 
Figure 2.1 Schematic representation of (A) microsphere and (B) microcapsule. 
In making microspheres, the API is mixed with the excipients, before or during the 
manufacturing process. The most common processes are: spray drying, granulation, complex perfect 
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spheres and spray congealing. Granulation is a process in which particles are made to adhere to each 
other, resulting in larger particles. In the absence of liquids this is called dry granulation, in the 
presence of liquids this is called wet granulation. Therefore there are many methods for granulating 
particles, high shear granulation, roller compaction, hot melt granulation, to name a few. The 
appropriate method needs to be chosen based on the material to be granulated andthe desirable granules 
properties. More recently, complex perfect spheres (CPSTM) have emerged as a proprietary method by 
Glatt where the mixture of API and excipients is densified and spheronized by an orbital motion 
created by air suspension[55]. Spray-drying refers to a solution or suspension sprayed into a hot 
chamber where the microspheres are formed by evaporation of the solvent in the hot environment 
during the downward fall in the chamber[50]. The microspheres produced by spray-drying generally 
have irregular geometry and porous surfaces due to the evaporation of the solvent[56]. Spray 
congealing is a similar process to the aforementioned spray drying, but in this case molten waxes or 
fats are sprayed into a cooled chamber, which solidify during their fall towards the bottom of the 
chamber where the microspheres are collected. The API might be insoluble or soluble in the matrix. If 
the API is soluble in the matrix, upon cooling, the API will be dispersed in the matrix. If the API is 
insoluble in the molten matrix, it will be embedded in the core or distributed in the matrix[56]. A 
specific case is melt-spray congealing (MSC). MSC (Figure 2.2) is a process in which a hot molten 
mixture is atomized by a spinning disk atomizer and the molten droplets congeal to form solid 
microspheres. The major disadvantage is that one must ensure API stability at high processing 
temperatures, but if this is assured, it produces microspheres within a tight span of particle size 
distribution. 
 
Figure 2.2 Schematic representation of MSC to produce microspheres. Adapted from Lo et al.[57] 
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2.3 Coating formulation 
There are numerous applications of coating, including drug layering, modified release coating, 
physical and chemical protection, aesthetic purposes, taste masking and enhanced identification of 
drugs[58]–[61]. The properties of the coating material are essential to the successful coating of 
microspheres. It is essential to select a coating formulation that exhibits good film forming properties 
but low agglomeration tendencies[62] to ease processing of the coating. This section will focus on the 
main constituents of a coating formulation: solvent, polymer type, placticizer, anti-tack agents and 
water-soluble additives. This section also aims at introducing the main coating formulation aspects 
(viscosity and solid content) impacting film-formation and the ability of the coating to be processed to 
achieve efficient taste masking.  
2.3.1 Solvent 
Polymers may be applied in organic or aqueous solution or suspension. The use of organic 
solvents has been decreasing since the 1970’s[50], as a result of toxicity and environmental pollution 
concerns, danger of explosion and  occupational hazard for the workers having to handle the volatile 
solvents[50], [60]. This helps to explain the growing popularity of aqueous based coatings, even 
though aqueous coatings also lead to problems of their own, such as long drying times at higher 
temperatures than organic solvents[50]. 
2.3.2 Polymer 
It should not come as a surprise that the film coating polymer is the most critical component of 
the coating solution, as different polymers may impact different drug release profiles[50].  
Some of the key attributes that the film polymer should possess are listed below[61]: 
1. Provide uniform film forming capacity (low porosity) 
2. Be compatible with the product substrate, providing chemical and physical stability of 
the end dosage form 
3. Allow drug release at the intended action site 
4. Have low viscosity (in order to facilitate atomization) 
5. Be stable in the desired solvent 
For taste masking purposes, the polymer should not allow the release of the API in the oral 
cavity, but it should allow the release of the drug in the expected absorption site (intestine or 
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stomach)[27] in order not to hinder drug bioavailability. Bioavailability is defined as the fraction of an 
administered dose that reaches the systematic circulation[32].  
Traditionally, water soluble polymers (polymeric solutions) have been used for taste 
masking[32]. They are used as physical barriers to delay drug release. However, their efficiency to 
block the interaction between the bitter API and the taste receptors is quite limited. They are expected 
to enable a fast dissolution rate irrespectively of the medium, being that the thickness of the coating 
will be the main factor determining the rate of release[25]. Joshi et al. [32] have reported that a 
minimum coating thicknesses of 10µm needed to be applied for this type of polymer. Water-soluble 
polymers used for taste masking include derivatives of cellulose (hydroxyethyl cellulose, 
hydroxypropyl methyl cellulose), polyvinyl alcohol and polyethylenglycol[32].   
Polymeric suspensions of water-insoluble polymers have also been used for taste masking, 
like, ethyl cellulose, cellulose acetate and polyvinyl acetate [32].  They have mostly been used in 
controlled-release dosage forms. Advantages of these systems include decreasing dosing frequency and 
thus enhancing adherence to the therapeutic regime[63]. Film thickness is especially critical in the use 
of water-insoluble polymers as there is a higher risk of affecting bioavailability. The other extreme 
situation of system failure would lead to dose dumping, this is when the coating is compromised and 
the entire drug load is rapidly released.  
A third category of polymers used for taste masking is pH dependent polymers. pH dependent 
polymers have ionizable functional groups. They will dissolve when a sufficient number of those 
functional groups are ionized. Films of reverse enteric polymers are cationic polymers that have a 
ionizable tertiary amine as functional group. Making these polymers insoluble at the neutral pH and 
ionizable in acidic pH, providing an effective barrier against the movement of drug molecules to the 
surface and water molecules to the core[32] at saliva pH. Saliva pH is generally in the range of 6.2 to 
7.6[64]. Examples of these polymeric systems are methacrylic acid copolymers, based on methacrylic 
and acrylic acid[65], such as Eudragit E® 12.5, Eudragit® E 100, Eudragit® E PO, Eudragit® E PO 
ReadyMix and Kollicoat SmartSeal® 30 D. Films of enteric coatings (anionic polymers) on the other 
hand are highly stable under acidic pH, but break down rapidly at less acidic pH[66]. They are 
generally used to target drug release in the intestinal track, protect the API from hydrolysis in the 
stomach and protect the stomach to irritating APIs. Enteric polymers used in taste masking are sodium 
alginate, shellac, cellulose acetate and carboxymethyl cellulose to name a few[32]. 
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2.3.3 Plasticizer 
The suitability of a plasticizer depends on its interaction with the polymer chains[50]. A 
suitable plasticizer must be soluble with the polymer. For aqueous-based dispersed systems, the 
plasticizer must partition into the polymer phase to ensure miscibility. 
The plasticizers action is based on molecular interactions with the polymer chains. Plasticizers 
weaken intermolecular attractions between polymer chains[63]. Plasticizers facilitate coalescence of 
discrete polymer spheres of aqueous based dispersed systems in film forming processes, by increasing 
film elongation. 
The glass transition temperature (Tg) is the temperature at which the mechanical properties 
change from stiff and brittle to soft and elastic[60]. At temperatures above the Tg, polymer chain 
movement is increased and the film behaves as flexible material[60]. By lowering the Tg of the 
polymer, plasticizers decrease both elastic modulus and tensile strength[50].  
Plasticizers are thus a key excipient of the coating formulation, as they reduce the brittleness of 
the polymer and reduce the propensity of cracking[61] by promoting the formation of an uniform film. 
Attention should be paid to the level of plasticizer used, because high plasticizers amounts 
might lead to agglomeration problems during the coating operation due to the ease with which the coat 
can deform[50]. Joshi et al. [32] reported that above the optimum level of plasticizer the deposited film 
would present molecular scale holes, reducing the films taste masking efficacy. 
Generally, polymer suppliers will have recommendations regarding the plasticizer to use and 
its level for the coating formulation[61]. Some of the most common plasticizers include: Polyethylene 
Glycol (PEG), Propylene Glycol (PG), Triethyl citrate (TEC), Tributyl citrate (TBC), Acetyl triethyl 
citrate (ATEC), Acetyl tributyl citrate (ATBC) and Dibutyl sebacate (DBS). 
2.3.4 Anti-tacking agents 
Anti-tacking agents are materials that are able to reduce agglomeration or sticking of particles 
during processing and subsequent storage. They can be used directly in the coating solution or added in 
a dry blending step at the end of the coating, to prevent agglomeration during overtime. Magnesium 
stearate, talc and kaolin are frequently used anti-tack agents[50]. 
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2.3.5 Water-soluble additives 
Water-soluble additives include low and high molecular weight compounds. Low molecular 
weight water-soluble additives include sucrose, lactose, sorbitol, mannitol, sodium chloride and 
calcium phosphate[50]. While high molecular coat weight gain compounds commonly used are 
polyethylene glycol, hypromellose and hydroxypropylcellulose, both classes of additives have the 
same end goal – to enhance drug release rate, but slightly different mechanisms of action. Pores are 
channels that form in the coating and increase the water permeability, thereby accelerating the API 
release. While low molecular weight compounds will dissolve in aqueous medium and leach out of the 
coating forming pores, high molecular coat weight compounds will also form pores, but not leach out 
of the coating, the latter can also result in the swelling of the coats, compromising the coating integrity.  
2.3.6 Viscosity 
The viscosity of the coating is intrinsically related to its composition as it is dependent on the 
solid content, the type of polymer and weight of polymer used. Viscous coating preparations have 
poorer flow properties and may increase tendency for nozzle clogs (see Figure 2.3), forcing several 
stops during the coating process and promoting unwanted agglomeration of the particles being 
coated[50]. 
As the viscosity of a solution increases (above 200-250 cps[61]), for a constant atomization 
pressure, the droplet size distribution produced by the spray guns will increasingly become wider, due 
to the production of larger droplets. If the atomization air pressure is adjusted, it can compensate this 
effect. Larger droplets may overwet the surface of the particles, potentially resulting in agglomeration 
or, under extreme conditions, wet quenching of the bed, that is if wet agglomerates are too strong to be 
fragmented and too large to be fluidized, then regions of the bed may de-fluidize and stick together as 
large wet clumps[67]. For coatings with a viscosity greater than 350 cps[61], the presence of larger 
droplets will have to be compensated with an increase of temperature to promote evaporation and 
prevent the over-wetting of the product. Viscous coating preparations are also difficult to spread onto 
the cores, hindering coalescence of the film and thus forming inconsistent coats[50]. All in all, this will 
lead to a lower-mass coating efficiency and a rougher film surface[61]. 
2.3.7 Solid content in film formation 
The concentration of solids in the coating suspension has an influence on the quantity of 
solvent that must be removed from the coating during the process. A low level of solids can increase 
the process time required to provide a protective film coating. A high level of solids can potentially 
2.4 FLUID BED WITH WURSTER COATING 19 
 
reduce the volume of coating formulation to be used and thus, reduce process time. However, when 
trying to coat with a coating formulation based on a high solid content at low coating level (low 
percentage of weight gain), it can be difficult to achieve an acceptable film coating uniformity[61]. A 
high level of solids can also lead to an increase of viscosity, which in turn might lead to the processing 
issues mentioned in the above sub-section.  
2.4 Fluid bed with Wurster coating 
In the 1950s, coating was performed in top spray granulators, where the spray nozzle is placed 
on top of the product chamber[47].The spray nozzle is located in the expansion chamber and the 
spraying droplets travel countercurrently to the fluidizing air[68]. 
During the 1960s, work was done towards the modification of the fluid bed coating unit to 
spray coating liquid from the bottom. Wurster invented bottom spray coating with an insert, also called 
the Wurster system (in his honor), which reduces the potential for agglomeration[47]. When coating 
without the insert, it was observerd that the spray system increased considerably the collision between 
particles and droplets, resulting in a higher material efficiency for tablet coating. For smaller particles, 
such as microspheres, the risk of agglomeration is increased, as particle motion becomes disorganized 
and loses its regular and circulatory pattern[68]. As such, due to the high concentration of wet particles, 
agglomeration is favoured. 
In Wurster systems, a column is placed above the gas distributor plate which promotes the 
circulatory movement of the particles being coated. In order to promote a higher central air velocity 
through the column, the area of the air distribution plate located directly under the column has higher 
perforated area than the periphery region, creating a region of lower pressure to which the particles are 
drawn and lifted up the column[45]. The nozzle is placed in the center of the gas distributor plate and 
the liquid droplets are sprayed concurrently with the fluidization air[68]. Contact between droplet and 
particle, spreading of the droplet of coatings onto the particle, coalescence of the coating and 
evaporation of the solvent (Figure 2.3 (B)), are occurring almost simultaneously during the coating 
operation[46], [47]. The drying of the wetted particles is done with the hot air that is also helping the 
fluidization[45], [47]. The dried solid matter which remains on the surface of the particle forms the 
film coating. As on the exit of the partition the fluid bed cross-section is suddenly enlarged, air velocity 
decreases and the particles decelerate in the expansion chamber, falling outwards freely in an inverted 
U-shape trajectory back onto the product bed staging area[45], [47]. The particles flow downwards in 
the annulus (staging area)[69]. Note that in order to avoid sticking and agglomeration, the coating film 
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must be dry enough when reaching the staging area. The cycle starts over when the particles re-enter 
the partition column through the partition gap and repeat the fountain-like cyclic flow until the desired 
coating level is achieved[45]. A layer of coating is applied with several passes through the spray, in 
order to produce complete coverage of the surface (layering)[46]. In coating, the main goal is not to 
change the particle size distribution, but to functionalize the particles being coated. When coating, the 
aims are to have an uniform distribution of the film and consequently particle size, to achieve an 
efficient evaporation, to inhibit core penetration by solvents and agglomeration[46], [61]. 
Agglomeration is something that is unwanted in a coating operation. It happens if a liquid bridge is 
established between two particles and remains until complete drying. So the now solid bridge has to be 
strong enough to resist mechanical stresses from collisions with other particles[45].  
Figure 2.3 (A) is a schematic representation of the above described particle trajectory and the 
coating process occurring in a Wurster coater. 
 
Figure 2.3 (A) Particle trajectory during the coating process in a fluid bed with a Wurster insert and (B) microlevel process 
occurring during coating adapted from Werner et al.[70] 
The application of a film to a solid is a complex process, involving several phenomena – 
particle dynamics, mass and heat transfer[47]. The performance of the coating operation should take all 
these aspects under consideration, however the most usual approach is to define coating efficiency as 
simply material efficiency (Ec), defined in equation (2.1) [47]. 
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𝐸𝑐 =
𝑊𝑐
𝑊𝑐𝑠𝐷𝑚
   [𝑑𝑖𝑚𝑒𝑛𝑠𝑖𝑜𝑛𝑙𝑒𝑠𝑠] 
(2.1) 
𝑊𝑐 = 𝑊𝑝 (
𝑤
1 − 𝑤
) [𝐾𝑔]  (2.2) 
In equations (2.1) and (2.2) [47], 𝑊𝑐  is the deposited mass of coating [Kg], w the coating 
content of the microspheres [Kg/Kg], 𝑊𝑝  the mass of core material [Kg], 𝑊𝑐𝑠  the mass of coating 
solution [Kg] and Dm the coating solution dry matter content [Kg/Kg]. Note that, in the above 
mentioned equations, there is no information regarding the energy balance or the quality of the coating 
itself, hence the name material efficiency. 
2.4.1 Batch size 
Fluidization is affected by batch size. A useful limit to consider is working capacity. Working 
capacity refers to the final batch weight. In the case of the Wurster coating process, this capacity refers 
to the volume outside the column. At least 40-50%[46], [61], [71] of the working capacity of the 
Wurster column should be occupied by when initially loading the batch. This loading is a guideline 
that aims at having a sufficient quantity of particles inside the partition to accumulate the maximum 
coating solution droplets and to avoid the premature coating drying phenomenon or depositing of the 
coating in the partition walls[69]. 
It should be referenced that the 40% limit is typically used for high coating levels. When the 
coating level is less than 10% w/w, then the advised range should be 60-70%[71] of working capacity. 
Working capacity can be calculated by equation (2.3)[61], where B is batch size (g), r1 the 
radius of the chamber [cm], r2 the radius of the Wurster partition [cm], L the length of partitions [cm] 
and 𝜌𝑝 the bulk density of the particles [g/cm
3]. 
𝐵 = 𝜋(𝑟1
2 − 𝑟2
2)𝐿𝜌𝑝 [𝑔]  (2.3) 
In the case of production scale, it is possible for the coaters to have multiple Wurster columns, 
thus it becomes necessary to multiply the radius of the partition in Equation 2.3 by the number of 
partitions[69]. 
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2.4.2 Air flow rate/Air velocity 
The air flow that fluidizes the cores within the coating chamber will also dry the liquid film 
coat deposited onto cores during drying[50]. Promoting adequate fluidization depends on, not only the 
mass of material to be coated, but also, the tackiness of the coating being applied[71]. Note that as 
more coating is applied, the mass increases, which might lead to an increase on the requirements for 
fluidizing air. On the other hand, tacky coatings can increase the drag forces on coated particles and 
potentiate agglomeration. In both cases an increase of fluidizing air can be used to offset these 
issues[71]. However, if set too high it may increase the erosion of friable cores. 
Starting from a fixed bed (at a fixed tube-to-bottom height), particle flow is secured by the air 
flow rate[47], orifice plate configuration and Wurster height. When increasing the gas velocity, a point 
will be reached where the drag force exerted by the gas upon the particles counteracts the weight of the 
bed: this is the beginning of the fluidization and the corresponding gas velocity is called minimum 
fluidization velocity. Since the substrate is transported up through the Wurster partition, the air must be 
well above the minimum fluidization velocity. The upbead region was characterized by Geldart and 
Rhodes[72] as a vertical pneumatic conveyor. The process is an entrainment of particles in the 
fluidization medium (usually air). The flow of particles into the upbed region (and thus the solid mass 
flow per unit of area in the upbed region) is controlled by the Wurster partition height[73]. In the 
Wurster column, typically, it will be a dilute pneumatic conveying process. Due to the usual height of 
the Wurster, the flow is not fully developed when the particles leave the column[73]. When the 
particles leave the upbed region to enter the expansion region, the air velocity should drop to a level 
well below the minimum fluidization velocity (umf). This is what allows the particles to fall in a 
counter-flowing fluidization medium, towards the downbed region[73]. When leaving the Wurster, a 
minimum height (the transport disengagement height) is required to avoid entrainment of the 
particles[73], [74]. This is the reason why most fluid-bed apparatus are designed so that they have a 
significant larger diameter in this region. This will enable the air velocity to be well lower than the 
minimum fluidization velocity. The downbed region is a slightly expanded bed. Depending on material 
type (in Geldart’s classification of powders[73]), the bed will expand more or less[73]. It is in this 
region that the particles will most likely tend to agglomerate, if the film is not fully dried. The control 
of the air flow rate in this downbed region is achieved by the hole area in the bottom plate under the 
downbed region versus that under the upbed region.  
The choice of velocities, and consequently of air flow, will have to take the above 
considerations of the desired fluidization pattern. By making use of flow regime diagrams one can 
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make an initial choice of the appropriate air flow to be used. Figure 2.4 [75] shows the charts to map 
the different flow regimes in terms of the dimensionless variables dp* and u*, defined in equations 
(2.4) and (2.5), respectively; dp* is the dimensionless particle size and u* is the dimensionless gas 
velocity. In the equations, dp is the particle size [m], ρg is density of the gas [Kg/m
3], ρs is the density of 
the solids [Kg/m3], g is the gravitational constant [m3.Kg.s-2],µ is dynamic viscosity [Kg.(m.s)-1]. 
𝑑𝑝
∗ = 𝑑𝑝 (
𝜌𝑔(𝜌𝑠−𝜌𝑔)𝑔
𝜇2
) [𝑑𝑖𝑚𝑒𝑛𝑠𝑖𝑜𝑛𝑙𝑒𝑠𝑠]   (2.4) 
𝑢∗ = 𝑢(
𝜌𝑔
2
𝜇(𝜌𝑠−𝜌𝑔)𝑔
)
1
3⁄  [𝑑𝑖𝑚𝑒𝑛𝑠𝑖𝑜𝑛𝑙𝑒𝑠𝑠]  (2.5) 
 
Figure 2.4. Flow regime diagram for whole range of gas-solid contacting. Letters C, A, B and D refer to the Geldart 
classification of solids[75]. 
The charts have been put together by the works of several researchers to show the onset of 
fluidization and terminal velocity (ut) in bed of single-sized particles and include Geldart classification 
of solids. Geldart[74] classified powders into four groups according to their fluidization properties at 
ambient temperature. From smallest to largest particle size they are groups C, A, B and D. Group C 
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comprises cohesive or very fine powders where normal fluidization is extremely difficult to achieve, 
due to high interparticle forces. Group A powders fluidize easily at low gas velocities and controlled 
bubbling at higher gas velocities. Group B powders fluidize well with vigorous bubbling. Finally group 
D powders are difficult to fluidize giving rise to large exploding air bubbles or severe channeling 
(spouting) behavior. 
In conclusion, proper product circulation should be safeguarded by adjusting (among others) 
the air velocities (or rather air flows) in the different transport regions of the bed.  
2.4.3 Coating Temperature 
The coating temperature, that is the temperature in the product bed, is an indirect parameter, as 
it cannot be adjusted directly. The product bed temperature results from interplay of inlet air 
temperature and spray rate. Nevertheless, as the film coating is forming in the product bed, it directly 
affects the end product quality. 
At optimal coating temperature, solvent evaporation happens at a rate that is slow enough for 
adequate coalescence of the polymer to the cores[50], but fast enough to avoid agglomeration. 
The minimum film-forming temperature (MFFT), is the minimum required temperature to 
cause coalescence of a polymeric solution to form a film[60]. Below this temperature, a polymeric 
dispersion will form an opaque, discontinuous material upon solvent evaporation. At temperatures 
above the MFFT, a clear continuous film will be formed.[76] If the operating temperature is lower than 
the minimum film-forming temperature, polymer particles may dry before coalescing, forming 
discontinuous porous films. An opaque or white powdery material is formed upon water 
evaporation[60]. 
2.4.4 Liquid flow rate and atomization pressure 
Typically the nozzles used in the fluidized air are pneumatic binary nozzles: liquid is supplied 
at a low pressure and is sheared into droplets by air[46]. Pneumatic atomization is the process of 
producing sprays by the disruptive action of a high velocity gas upon a liquid stream[77]. In binary 
nozzles, the two fluids involved are air and coating. One can control droplet size distribution, simply 
by adjusting liquid flow rate and atomization pressure. The atomization of a liquid is accomplished by 
creating a high relative velocity between the liquid and the surrounding air[77]. In general, higher 
relative velocities will result in smaller size droplets. However, when set too high the droplets might 
end up being so small that they might dry before they reach the core[50]. Yet if set too low, larger 
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spray droplets will form, which can more easily form liquid bridges between cores[50]. A drawback of 
using this type of nozzle is that the atomized air will also contribute (to some extent) to the evaporation 
of the coating solvent, thus increasing the droplet’s viscosity, which in turn can inhibit spreading and 
coalescence once in contact with the raw material[46]. 
Dybahl Hede et al.[77] have presented a comprehensive literature review with empirical 
mathematical correlations that can be used for the determination of mean droplet size and droplet size 
distributions by different authors. However, as it is stated by the authors of this review, “it is not in any 
way obvious which correlation that predicts the mean droplet size best in a given situation”[77], as 
many of this correlations have been developed for specially designed nozzles. The usefulness of the 
correlations needs to be assessed on a case-by-case basis. 
Maximal liquid spray rate depends on coatings’ and particles’ physiochemical properties such 
as surface tension, viscosity and specific area, and of drying characteristics such as glass transition 
temperature and minimum film forming temperature[45]. Nevertheless, the value for maximal liquid 
spray rate can be obtained in an experimental basis and it is defined as liquid spray flow rate used just 
before agglomeration or collapse of the bed is observed[45]. 
2.4.5 Humidity 
Drying capacity for aqueous coating systems is affected by the fluidization air, temperature and 
absolute humidity, being that air is the drying agent. Like in any drying operation, the drying of the 
coating onto the particles contains two fundamental and simultaneous processes: heat transfer to 
evaporate the solvent and mass transfer as liquid or vapor within the solid and as a vapor from the 
surface of the solid to the air.  
During the drying, the rate of evaporation from the wet surface to the surrounding air is 
determined by the difference between the water vapor pressure at the liquid surface and the vapor 
pressure in the surrounding air. In an enclosed space, evaporation will continue until the two vapor 
pressures are equal. However, in a case like the one of a fluidized bed, unsaturated air is constantly 
being supplied, and thus the wet surface will reach an equilibrium temperature at which the cooling 
effect due to evaporation is equal to the heat transfer to the liquid by conduction and convection by the 
air. 
An indication of the water content in the air is relative humidity that is defined as the 
percentage of partial pressure of water vapor in the air divided by the saturated vapor pressure of water 
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at the same temperature[78].  As the name indicates, relative humidity measures the amount of 
moisture in the air against a maximum amount of moisture in saturated air.  
Another point to consider is that if the air is too humid, the spray rate that can be used is 
limited, otherwise overwetting will occur. If the humidity is too low, static might build up[61] and 
affect particle flow.  
2.4.6 Curing conditions 
After coating, it is usual to perform a curing step, which allows more residual water to 
evaporate and help the polymer particles to coalesce[50] which leads to a denser film coat. This 
phenomenon is accelerated at elevated temperatures, reason why this operation is typically done in an 
oven at controlled temperature and relative humidity. The curing temperature should exceed the 
minimum film forming temperature but not the glass transition temperature, as beyond the latter, the 
polymer will become soft and sticky, leading to agglomeration. 
2.5  Quality-by-design and process analytical technology 
Traditionally, the pharmaceutical industry has been reluctant to introduce innovative systems 
into the manufacturing sector. One of the reasons often pointed out is the rigid regulatory system 
surrounding the drug approval process, where the company must provide a detailed manufacturing plan 
and any alteration to it must be approved by the regulatory body around the world[79]. This mindset 
has gradually been changing over the past decade, or so, and we are now in a new era for the 
pharmaceutical industry, where the regulatory bodies give incentives to improve product quality and 
process performance. Figure 2.5 attempts to illustrate the main milestones in the evolution of QbD, 
being that the International Conference Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) is of special importance, given that it brought together the 
regulatory authorities of United States, Europe and Japan. 
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Figure 2.5 Evolution of the regulatory framework for pharmaceutical products. 
In the 1950s, Juran was a pioneer in developing the QbD principle[80]. The QbD approach 
makes use of sound science and quality risk management to develop both product and process so that 
the process is developed to meet the desired quality specifications [21]. The main idea is that if the 
relationships between process settings and material attributes are fully understood, quality issues can 
be anticipated and promptly mitigated. A process is generally considered well understood when[81]: 
1. Product quality is based on clinical performance; 
2. All critical sources of variability are identified and explained; 
3. Variability is managed by the process;  
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4. Product-quality attributes can be accurately and reliably predicted over the design 
space established for materials used, process conditions, manufacturing, environmental 
and any other relevant condition. 
Quality risk management is defined in the ICH guideline Q9 as “a systematic process for the 
assessment, control, communication and review of risks to the quality of the drug product across the 
product life cycle”[82]. Some of the recommended tools are Ishikawa diagrams, failure mode analysis, 
effects and criticality analysis, fault tree analysis, hazard analysis and critical control points, hazard 
operability analysis, preliminary hazard analysis, risk ranking and supporting statistical tools. The 
usefulness of each of these tools depends on the prior knowledge of the process, risk assessment stage 
and complexity of the issue to be addressed.  
 
Figure 2.6 Three step implementation of QbD, with the objectives of each step[81]. 
Figure 2.6 illustrates the stages of implementation of QbD: Design, Analyze and Control. The 
design stage starts with the identification of the CQAs that are being affected by the process step along 
with the CPPs that have been determined to affect the CQAs. This step aims at creating (or further 
developing) process understanding and it is critical for the next phase: the choice of a suitable analyzer. 
In the analysis stage, a suitable analyzer is chosen to monitor the CQAs and the CPP. The final stage is 
control. It involves a control scheme design based on process understanding such that the data from the 
analyzer can be used for making real-time process decisions, so that consistent process performance 
and product quality can be achieved. 
Process Analytical Technology (PAT) has been defined as “a system for designing, analyzing, 
and controlling manufacturing through timely measurements (i.e., during processing) of critical quality 
and performance attributes of raw and in-process materials and processes, with the goal of ensuring 
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final product quality” [24]. A goal of the PAT framework is to identify and handle sources of 
variability of the process to provide a foundation for QbD implementation.  
Process analysis measurements can be classified as: in-line, sample is analyzed in situ[24]; on-
line, sample is diverted from the main process, analyzed and may be returned; at-line, the sample is 
removed and analyzed close to the process; and off-line, the sample is removed and analyzed away 
from the process. Traditional methods to monitor the above mentioned parameters are limited to either 
endpoint analysis or limited sample collection. With the implementation of PAT tools, the goal is to get 
real-time analysis of the whole process (in-line monitoring). For PAT tool applications, it is necessary 
for the analytical results to be available in the time-frame necessary to facilitate making decisions in 
real-time[81]. 
2.6 Design of experiments 
Design of experiments (DoE) is a structured, organized method to plan and conduct 
experiments and analyze the resulting data using the statistical approach in order to determine the 
factors that affect a process, its interactions and how they affect the output of that process[83]. DoE is a 
much more efficient way to achieve process knowledge[84] when compared to changing one factor at a 
time. Risk analysis should be the starting point for allocation of resources for this activity. Prior 
knowledge about the process should be used to define the appropriate range to define the design space, 
so that areas where it is impossible to operate are excluded[23]. 
Montgomery[83] has described a process by the means by which we transform a series of 
inputs in outputs, under the influence of a series of factors that can be categorized as controlled or 
uncontrolled. Noise corresponds to uncontrolled unavoidable variation which is expressed through the 
experimental error. Nuisance factors are factors that may influence the experimental response but in 
which we are not particularly interested. It is still important to be aware of what these factors might be 
so that we can reduce or even eliminate the variability transmitted from these nuisance factors to our 
response. Blocking is a basic design technique that is used to this effect. A block is defined as a set of 
homogeneous experimental conditions. 
The impact of controlled factors on the quality of the product can be used to help identify 
CMAs and CPPs. In DoE approach, the controlled inputs are systematically varied in order to 
determine their effect on the responses. DoE can also be run for the purpose of optimization, that is to 
find a set of CMAs and CPPs level that will result in the desirable quality target product profile 
(QTPP). In confirmation experiments, DoE is used to confirm that the system behaves in a way that is 
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consistent to previous knowledge. In discovery experiments, DoE is used to determine the impact of 
new variables, materials or levels in the CQAs. Finally, DoE can be used for robustness testing in order 
to address how we can set control variables to minimize the variability in our response to factors that 
we are not able to control very well. 
The choice of the design is dependent on the type of parameters under study, the number of 
replicates and the run order for the experimental trial, determining if blocking is required or not. 
Choosing a design also implies thinking of the quantitative relationship (empirical model) that will 
describe the results. DoE seeks to approximate reality with a mathematical model, the simplest of 
which is a linear model. The model is a quantitative relationship that is established between inputs and 
output. Linear models are often called main effect models and are used extensively in screening and 
characterization experiments[83]. Another type of design that is used in screening experiments is the 
D-optimal design[85]. Generally, a D-optimal design is a computer-aided design that minimizes the 
variance of the model regression coefficients[83]. It does so by maximizing the determinant of XX’, 
where X is the data matrix of independent variables, that is the controlled factors under study evaluated 
at specific levels in the design space. They are especially useful in situations where the design matrices 
are not orthogonal and the effect estimates are correlated[86].  
2.7 Multivariate data analysis 
Chemometrics, as defined by Massart et al.[87], “is a chemical discipline that uses 
mathematics, statistics and formal logic (a) to design or select optimal experimental procedure; (b) to 
provide maximum relevant chemical information by analyzing chemical data; and (c) to obtain 
knowledge about chemical systems”. 
Multivariate data analysis (MVDA) is thus involved in the process of collecting and extracting 
information from data. The first step is to collect “good data”, meaning data with a reasonably low 
amount of error for the purpose that is being given to the data. Otherwise the information may be 
uncertain or even worst, wrong. 
As stated in point (a) of the chemometrics definition, there is a need to choose which 
experiments are relevant to the problem being studied. To this end, the chemometrician will resort to 
design of experiments (DoE). The experiments will generate data which the chemometrician will use to 
extract information (point (b)) and which will give information about the system, as stated in point (c) 
of the same definition. 
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The first step for extracting information or for a data analysis is to display the data. Usually, 
the objects (samples) are represented as rows and the variables as columns. In many cases there will be 
more variables than objects since chemical systems are usually multivariate systems. Simplistically this 
means that several measures are made simultaneously. That is why chemometrics falls into the 
“multivariate analysis techniques” category. [88] One of the main advantages of chemometrics is that it 
offers methods that allow reducing the dimensionality of the data, such as Principal Component 
Analysis (PCA). 
The data analysis will often lead to the formulation of hypothesis that will need to be tested 
(hypothesis testing), or it may have the goal to describe quantitatively one variable (or more) in terms 
of the others (calibration/regression), or even to try to group the objects according to the variables 
measured (classification). The obtained models always have to be validated. This is often achieved by 
the development of statistical tools, numerical methods, computer technology together with chemical 
and biological knowledge (in order to make interpretations). 
Before describing some of the chemometric methods used in this work, the nomenclature will 
first be explained. In this document, vectors are indicated by bold lower-case characters, two-way 
matrices by bold capitals and finally three-way arrays by underline bold capitals.  
2.7.1 Principal component analysis 
PCA is a favorite tool for data exploration, that is to say, to compress and retrieve the essential 
information and to display (the relevant information) in a clearer way than displaying the same 
information of each of the variables individually. 
Principal component analysis (PCA) is able to reduce the dimensions by projecting the data 
into a “new set of variables” called principal components (PCs)[87], which are linear combinations of 
the original X variables. The first principal component will capture the maximum variance of the data, 
in order to preserve, as much as possible, the structure originally presented.[87] 
Of course there will be some variation that is not captured by this first component (this will be 
in the residuals) thus one can calculate a second component that captures the second maximum source 
of variance in the data. This second principal component will be orthogonal to the first. Thus, the 
variable reduction is done by making linear combinations of the original variables. [87] 
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Mathematically, PCA can be described in the following way[88]: given a X data matrix with n 
rows and m columns, PCA decomposes it as the sum of r ti and pi, where r is the rank of the matrix. X 
will be given by equation (2.6)[88]. 
𝐗 = 𝐭𝟏𝐩𝟏
𝐓 + 𝐭𝟐𝐩𝟐
𝐓 + ⋯ + 𝐭𝐤𝐩𝐤
𝐓 + ⋯ + 𝐭𝐫𝐩𝐫
𝐓   (2.6) 
The rank of a matrix is the number of the non-zero rows obtained by reducing a matrix to its 
echelon form, so trivially r must be less or equal to the smaller dimension of X. The ti and pi vectors 
are known as scores and loadings, respectively. While the ti gives information about how the samples 
relate to each other, the pi gives the same information about the variables. The principal components 
(PCs) are the outer product between the ti and pi (tipi
T) and they are ordered according to the variance 
captured. 
When one is performing a PCA analysis, the goal is to explain the main sources of variation in 
the data and not to explain each detail and particularity of every sample. Therefore, the model is 
generally truncated leaving out a small amount of variance in a residual matrix. X will be now given by 
equation (2.7)[88]. 
𝐗 = 𝐭𝟏𝐩𝟏
𝐓 + 𝐭𝟐𝐩𝟐
𝐓 + ⋯ + 𝐭𝐤𝐩𝐤
𝐓 + 𝐄 = 𝐓𝐤𝐏𝐤
𝐓 + 𝐄   (2.7) 
The scores (ti) form an orthogonal set Tk and the loadings (pi) form an orthonormal set Pk with 
E being the residuals.  
The projection of the score vectors on a plan is called score plot, whereas the projection of the 
loading vectors on a plan is called loading plot. 
2.7.2 Regression analysis in the context of multivariate data analysis 
The regression problem: how to model one (or more) dependent variables, responses Y, by 
means of a set of predictor variables, X, is one of the most common problems that can be encountered 
in science and technology[89].  
In handling numerous and collinear X-variables, or predictors, and response profiles (Y), 
Partial Least Squares (PLS) Method allows for the investigation of more complex problems[89]. PLS 
seeks to find factors, latent variables (LV), which both capture and achieve correlation, by maximizing 
the amount of variance explained in X that is relevant for predicting Y[90]. 
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The NIPALS (Non-linear Iterative Partial Least squares) algorithm is perhaps the most 
intuitive way of calculating the scores T and loadings P, and an additional set of vectors known as 
weights, W[90] (see Figure 2.7). The PLS decomposition is started by selecting a column of Y, as the 
starting estimation for u1 (score of the first latent variable of Y). Each model parameter is iteratively 
estimated until convergence is achieved. Convergence is checked by comparing the scores t in X. After 
convergence, the entire procedure is repeated for the next latent variable (the NIPALS algorithm is 
given in for example, Westerhuis et al.[90] ). 
 
Figure 2.7 PLS method. The method will start by a first estimate of u, until convergence of t. 
PLS can also be written to look as a multiple regression model, given by equation (2.8)[89], 
where W* is W in terms of non-deflated X, 𝜷𝑷𝑳𝑺  the “PLS regression coefficients” and F the Y 
residuals. 
𝐘 = 𝐗𝐖∗𝐐′ + 𝐅 = 𝐗𝛃𝐏𝐋𝐒 + 𝐅   (2.8) 
The variable influence on projection (VIP) was developed as a parameter which summarizes 
the importance of the X-variables, both for X- and Y-models. The VIPs are a weighted sum of squares 
of PLS weights taking into account the amount of explained Y-variance in each dimension. 
Extensions to the PLS model, where additional sources of information could be added, have 
been found to be useful in the literature to monitor chemical processes[91], [92], particularly in cases 
where the number of variables measured on the same observations is very high and/or there are several 
groups of variables[93]. The advantage is that in addition to monitoring the whole process, we are 
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keeping the information segmented making it easier to detect,  isolate and identify causes for when a 
fault happens[90]. It seems only logical to break up a process that consists of many distinct sections 
(sources of information) into several X-blocks, one corresponding to a different source of information 
about the process. Nevertheless, it is ideal for the data to be analyzed jointly. For example, when 
acquiring multivariate data from different processing units within an industry, it is often relevant to 
determine how each processing unit influences final product quality along with assessing the impact of 
any given process variable occurring within that unit. 
An extension of PLS capable of taking these blocks into account is multiblock PLS (MBPLS), 
first proposed by Wangen and Kowalsky[94]. In MBPLS, the blocks are typically scaled to unit 
variance before being scaled a second time to compensate for varying block dimensions. While the 
blocks must all have the same number of observations, the number of variables may vary widely. To 
achieve this, they are divided by the square root of the number of variables in the blocks to achieve 
block scaling and allow a direct comparison between the blocks[90]. In MBPLS model, different 
scores for each data block are calculated; these are called sub-level-scores. With the block scores, it is 
possible to calculate the super-level scores. If the super-scores are used for the deflection of X and y 
blocks (Figure 2.8), then the predictive capacity is equal to an unfolded PLS model. Blocking the 
information like in MBPLS has the great advantage of simplifying the interpretation of the data by 
looking at smaller blocks of information and the relationship between them[95]. 
 
Figure 2.8. MBPLS method. Adapted from Westerhuis et al.[90] 
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Block importance for prediction (BIP)[93] is an extension of the variable importance on the 
projection (VIP). The general rule used is that when the blocks have been scaled, a block with a BIP 
much higher than 1 represents an important contribution to the model[93]. 
Statistical indicators should be used to evaluate the generated models. The root mean square 
error of calibration (RMSEC) gives an estimate of the average deviation of the model from the data, 
giving us an idea on how well the model fits the data. In contrast, cross-validation is a practical way to 
test the significance of a model[96]. In cross-validation, typically the data set used for calibration is 
splitted into different training sets to try to evaluate how the model would perform when applied to 
new data. The root mean square error of cross-validation (RMSECV) can be used to measure the 
predictive power of a model, making it a useful tool for initial model comparison. In order to be able to 
calculate the root mean square error of prediction (RMSEP), one needs to have available independent 
prediction set of samples that have known Y values. 
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Contributions to the thesis: This chapter is focused on describing the adopted methodology 
to study the relevance of coating formulation and Wurster process variables in the taste masking 
performance of a novel reverse enteric polymer (Kollicoat® Smartseal). It is important to point out that 
dissolution at pH 6.2 was used as a surrogate test for taste masking performance. This work allowed us 
to conclude that Kollicoat® Smartseal is a robust polymeric system (within the studied design space) 
and that the final microstructure of the applied film is critical for coating performance. 
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Titre en français : Étude du procédé d’enrobage de microsphères par lit d’air fluidisé dans un 
but de masquage de goût  
Résumé en français : 
Le goût est souvent cité comme un des principaux facteurs ayant un impact négatif sur 
l’adhésion thérapeutique des enfants. Les systèmes composés de microsphères enrobées sont des 
solutions prometteuses car ils fournissent des doses de PA divisées en de nombreuses unités 
posologiques plus petites permettant un dosage mieux adapté à la grande variabilité de poids des 
enfants de bas âges. Aux fins des présents travaux, les microsphères ont été enrobées avec du 
Kollicoat® Smartseal, un polymère entérosoluble inverse, qui agit pour minimiser ou empêcher la 
libération de PA à pH neutre dans la cavité buccale. Il en résulte un effet masquant du goût désagréable 
du PA. Sept variables clefs du procédé d’enrobage avec Wurster ont été sélectionnées puis évaluées par 
un plan d’expérience D-optimal et une analyse de la variance. Le pourcentage de PA libéré à pH 6,2 a 
été utilisé comme méthode de substitution pour déterminer la performance au chapitre du masquage de 
goût du Kollicoat® Smartseal. Les sept variables étudiées sont : la température du lit de produit, le 
débit d’air entrant, la pression d’air atomisé, le débit de l’atomiseur (paramètres du procédé), le taux 
d’enrobage, le niveau de plastifiant, la présence de solides dans la suspension d’enrobage 
(caractéristique du matériel) et le durcissement. Les résultats montrent que le niveau d’enrobage, le 
niveau de plastifiant, le débit et la température du lit sont les paramètres critiques du procédé et 
renforcent l’importance du durcissement pour réduire la variabilité entre les lots en favorisant la 
formation d’un film complet. Le lien entre les caractéristiques du matériau, les paramètres du procédé 
et les attributs de qualité a permis une meilleure compréhension des paramètres qui affectent le profil 
de libération du PA à pH buccal (in-vitro). Il a été démontré que tant l’épaisseur que la morphologie de 
l’enrobage ont un impact sur la dissolution dans 50 mM tampon phosphate de potassium. 
Mots clefs : Kollicoat® Smartseal, enrobage, lit d’air fluidisé avec Wurster, plan d’expérience 
D-optimal, microsphères, forme posologique pour des fins pédiatriques 
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3.1 Abstract 
Taste is routinely cited as one of the major contributing factors that negatively influence 
pediatric patient compliance. A promising solution is coated microsphere systems, which provide doses 
of active pharmaceutical ingredients (API) subdivided into a plurality of small dosage units. In this 
work, the microspheres were coated with Kollicoat® Smartseal, a reverse enteric polymer, which acts 
to minimize or prevent the release of API in the neutral pH of the oral cavity, which results in a 
masking effect of the unpleasant taste of the API. A screening of seven key variables in a Wurster 
coating process was evaluated by D-optimal design and by analysis of variance. The percentage of API 
released at pH 6.2 was used as a surrogate method for taste masking performance evaluation of 
Kollicoat® Smartseal. The seven studied variables were: product bed temperature, inlet airflow, 
atomizing air pressure, spray rate (process parameters), coating level, plasticizer level, solids in coating 
suspension (material attributes) and curing. Results show that coating levels and plasticizer levels are 
the critical process parameters and reinforce the importance of curing to reduce the overall variability 
within the batch by promoting complete film formation. The links between material attributes, process 
parameters and quality attributes were demonstrated to allow a better understanding of the parameters 
that affect the API release profile at mouth pH (in vitro). It was demonstrated that not only thickness, 
but also coating morphology have an impact on the dissolution in 50 mM potassium phosphate buffer 
at pH 6.2. 
Keywords: Kollicoat® Smartseal, Wurster coating, D-optimal design, microspheres, pediatric 
formulation 
3.2 Introduction 
Depending on the ability of a child to swallow a tablet, the pediatric oral formulations might 
differ, with liquid oral formulations being preferred for younger children (from birth) and tablets being 
preferred for older children (from 7 to 8 years old)[53], [97]. Oral liquid dosage forms usually make 
use of sweeteners, flavoring agents and acids to mask the unpleasant taste of active pharmaceutical 
ingredients (APIs)[2], [13]. Yet, according to more than 90% of pediatricians[13], the greatest barrier 
to complete pediatric treatment is still the palatability of the dosage form[13]–[15]. Moreover with the 
pediatric population including preterm newborns up to 18-year-old adolescents[14] and with 
appropriate dosing being based on the patient’s body surface area, it is not surprising that flexible oral 
dosage forms are preferred[2]. 
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As it has been identified in 0, microspheres have been acknowledged as a flexible platform 
technology[14], [17], since they can be administered to a wide range of the pediatric population as long 
as precise dose measurement and particle size control are achieved.  
As it was previously explained in section 2.1, there are four main taste masking principles: 
modification of formulation and/or pH, use of a physical membrane, chemical or solubility 
modification and solid dispersions[15]. In the field of pediatric oral dosage formulations, the two most 
common approaches are the use of physical membranes and modified formulations using sweeteners 
and flavors[26]. That being said, having the API dispersed into a matrix system, such as microspheres, 
can be classified as a solid dispersion approach. In theory, by having the API randomly dispersed 
within an inert solid carrier, the interaction between API and taste buds will be inhibited and thus mask 
the API’s taste. However, taste masking by solid dispersion is often incomplete because API located in 
the exterior surface of the microsphere can quickly dissolve in the oral cavity and interact with the taste 
buds. In practice, the extent to which taste masking is required will always depend on the 
physiochemical properties of the API, as well as its taste threshold[14], meaning that depending on the 
API, other taste masking methods might need to be applied. For solid oral dosage forms, the 
application of a uniform physical barrier is the most efficient way of successfully providing a palatable 
dosage form. Several technologies are described in the literature for coating microspheres such as 
microencapsulation[98]–[100], dry coating[40], [44] and fluid bed coating (or air suspension 
coating[58]) . The present work will focuses on fluid bed coating with a Wurster insert. The coating 
layers are formed during the recirculation of the particles through the Wurster column. For further 
details on the Wurster coating process, the reader is advised to see section 2.4. 
To produce an optimal coating, it is also essential to select a formulation that exhibits good 
film forming properties but low agglomeration tendencies[62]. Key coating formulation materials are 
polymer and additives. The polymeric system chosen for this work is the reverse enteric polymer 
Kollicoat®Smartseal 30D. Described in the literature is some work showing the effectiveness of this 
methacrylate acid copolymer [101]–[103] for taste masking. However, this work does not link the 
coating formulation and coating process to drug dissolution. Additives are generally used to facilitate 
processing of the polymer in order to promote film formation and improve mechanical properties of the 
polymer. Commonly used additives are described in sub-section 2.3.3 through 2.3.5 of this document. 
When developing a taste-masked formulation, the formulation scientist should keep in mind 
the desired body site (stomach or intestine) for drug release and absorption. The chosen taste masking 
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strategy should not impair the bioavailability of the drug. As mentioned previously, reverse enteric 
polymers dissolve at acidic pH, making them ideal for stomach specific drug delivery given that the 
gastric pH for fasted state is pH 1-2[104]. Reverse enteric polymers do not dissolve at mouth pH 6.2 to 
7.6[64]. 
One of the major challenges still associated with aqueous film coatings is the incomplete film 
formation that could lead to long-term physical stability issues[105]. To countervail this, it is usual to 
perform a thermal post-treatment (curing step), which results in stable release profiles upon 
storage[106]. This operation is typically done in an oven at controlled temperature and relative 
humidity. Figure 3.1 summarizes the key variables involved in the process[62]. 
 
Figure 3.1 Ishikawa diagram for formulation and process variables for the fluid bed coating of microspheres. 
The main objective of this work is to develop a fundamental knowledge of the parameters that 
affect the properties of the microsphere coating with a reverse enteric polymer (Kollicoat®Smartseal 
30D) and to determine their impact on the API release profile at pH 6.2 (in vitro representation of the 
behavior in the mouth). In vitro dissolution provides insight on how efficiently the barrier membrane 
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coating prevents drug release into the oral cavity[107]. In the fasted state, the stomach pH is around 
1.2[108]. The ability of the API to fully release at pH 1.2 was confirmed. However, it is not within the 
scope of this project to link processing conditions and bioavailability assessment. The parameters 
studied include both process parameters and coating formulation material attributes; curing and the 
quality of the coating was evaluated in terms of coating morphology. Coating morphology is also an 
important quality criteria, as an incomplete film will have pores and fissures in the coating[83] that 
impact the effectiveness of taste masking. The coating morphology is evaluated by thickness 
measurement, surface area analysis of the uncoated and coated microspheres as well as scanning 
electron microscope (SEM) imaging of cured microspheres. 
3.3 Material and methods 
3.3.1 Microspheres 
The chosen microsphere composition was as follows: 10% w/w crizotinib (Pfizer Inc.) (API), 
50% w/w stearyl alcohol (BASF, USA) (wax carrier), 10% w/w poloxamer 407 (Lutrol® F-127) 
(BASF, USA) (pore former) and 30% w/w microcrystalline cellulose (MCC) (FMC Corporation, USA) 
(filler). 
The blend of materials was fed to a twin-screw extruder forming a molten mixture. The 18 mm 
co-rotating twin-screw extruder (model MIC18PH, Leistritz Group, Germany) had a total of seven 
barrels and the temperature profile was as follows (from drive to end): 40-40-40-60-80-80-80 °C. The 
molten material in which the API was suspended was kept at 80°C and fed to a 4” conical spinning-
disk atomizer heated at 80 °C, spinning at 2250 rpm to form the droplets that, upon cooling at ambient 
air temperature, congeal to form the microspheres[57], [109] (MSC). The particles were then sieved to 
a diameter above 150 μm and below 600 μm. 
The same microsphere formulation, composition and manufacturing procedures were also used 
throughout the batches. The mean volumetric microsphere cores particle size were was 304.4±6.3 μm 
with a span of 0.61±0.02 for batches 1 to 17 and 314.0±4.7 μm with a span of 0.56±0.01 for batches 18 
to 21, after sieving. The span of a particle size distribution is a parameter that provides insight on the 
width of the distribution. Span can be defined as the difference of D90 and D10, divided by D50. 
Particle size distributions were determined by QICPIC (Sympatec GmbH, Germany), an automated 
particle analyzer based on dynamic image analysis.  In QICPIC, the samples are fed (through VIBRI) 
to the RODOS, a dry disperser (Sympatec GmbH, Germany) that is used to ensure the effective 
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separation of the microspheres. A high-speed camera then captures the particles within the frame and 
information can be gathered relative to particle size and sphericity of the particle[110]. 
3.3.2 Preparation of coating suspension 
The polymer system used for coating in order to achieve taste masking was 
Kollicoat®Smartseal 30D (BASF, Mississauga, Canada), an aqueous dispersion containing methyl 
methacrylate and diethylaminoethyl methacrylate co-polymer dispersion containing 30% of solids (dry 
polymer). Following BASF recommendations, the lipophilic antioxidant, butylated hydroxytoluene 
(Spectrum, Gardena, Canada) is dissolved in the plasticizer, triethyl citrate (Vertellus, Greensboro, 
USA) at 50 °C. The anti-tacking agent, talc (Sigma-Aldrich, Saint Louis, USA) was dispersed in 
distilled Milli Q water (Merk Milipore, Burlington, USA) by a homogenizer (Polytron PT1300, 
Kinematica, Switzerland). Stirring continuously, the talc and subsequently the mixture of antioxidant 
and plasticizer were added to the Kollicoat®Smartseal 30D. The suspension was stirred for at least two 
hours and then subsequently passed through a 200 μm sieve just before starting the coating operation to 
ensure no lumps were being introduced in the coating line that would potentially obstruct the nozzle 
during the coating operation. 
3.3.3 Experimental design 
Taking Figure 3.1 as a starting point, parameters related to the equipment design were 
excluded from this study given that only one coater was available to perform the experiments.  
As it is not feasible to include all the variables in a screening analysis, the curing conditions 
(time, temperature and air humidity) were not included in the study. Rather, the impact of curing was 
included as a binary choice: subsamples of the batches were either cured or left uncured.  
Thus, from the state of the art in fluid bed coating[62], [70], and by a process of elimination, it 
was decided that it was relevant to study the following seven process and formulation parameters:  
1. Product bed temperature (selected levels: 25.0-28.5-32.0 °C): 32 °C was the level 
established for a maximum inlet temperature of 65 °C, so that the bottom plate would 
not heat to melting-point temperature of the microspheres and 25 °C was chosen taking 
into account the minimum film forming temperature (MFFT) of the polymer 
dispersion[28]. The product bed temperature provides a more precise overview of the 
conditions at which the sprayed droplets coalesce and form a film barrier when 
compared to inlet air temperature. 
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2. Inlet airflow (selected levels: 40-50-60 m3/h): levels were chosen so that the flow 
regime[75] within the Wurster column[45], [47] would allow appropriate material 
transport in the upbed region. The two studied regimes were: fast fluidization, when 
airflow was set at 40 m3/h, and pneumatic transport, when airflow was set at 60 m3/h. 
Visual assessment of the flowability of the particles in the fluid bed confirmed the 
choice. 
3. Atomizing air pressure (selected levels: 1-2-3 bar):  levels were chosen in order to 
promote different droplet to particle ratios, given that the size of the droplets must be  
significantly inferior to the size of the microspheres to promote layered growth[67]. 
4. Spray rate (selected levels: 5-8-11 g/min): levels were chosen simultaneously with 
airflow and product bed temperature. Ensuring that product bed temperature could be 
kept within the chosen levels (above 11 g/min the temperature drops below 32 °C at 
maximum inlet temperature) and to keep to reasonable processing time (with 4 g/min 
the processing time to achieve a 23.6% w/w coat weight at 15.68% w/w solids in 
suspension would take 4 h).  
5. Coating levels (selected levels: 7.00-15.3-23.6% w/w): were chosen in order to 
promote a significant difference in coating thickness that would have an impact on the 
dissolution profile, but still keep relatively thin coatings (<20 µm).  
6. Plasticizer (selected levels: 12-16-20% w/w dry polymer): levels were chosen based on 
mechanical properties of the film[28], namely the minimum film forming temperature 
(ranging from 21 °C to 7 °C[28]) (helped chose the product bed temperature) and the 
percentage of elongation at breaking point (spanning from 50 and 250%[28]). 
7. Solids in suspension (15.68-19.60-23.52% w/w): levels were chosen in order to reduce 
the processing time. Total solids are considered as 30% of Kollicoat®Smartseal 30D, 
butylated hydroxytoluene, triethyl citrate and talc. By using a coating suspension with 
23.52% w/w solids versus a 15.68% w/w the process time is reduced by 70%. 
Based on those parameters, a seven factors D-optimal design[111] using two levels (high and 
low) as well as three center points was carried out in randomized order to identify and classify the 
critical formulation and process variables (Annexe I). The D-optimal design was calculated using 
Matlab R2010b (MathWorks, USA). 
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3.3.4 Coating of the microspheres 
The twenty-one batches were run in a GPCG-2 (Glatt GmbH, Germany) fluid bed fitted with a 
4” Wurster insert. Column gap was fixed at twenty mm from the air distribution plate (plate B). The 
coating suspension was continually stirred throughout the coating process and atomized by a Sclick970 
(model 0 S3) with a 4 mm spacer and 0.8 mm liquid tip. The initial batch size was 400 g. Process 
parameters were recorded manually every 5 min until the desired suspension coat weight loss was 
achieved and the duration of the runs spanned from 20 min to 3 h. 
The coating weight to be applied was determined using equation (3.1):  
𝑚𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛 =  
𝑤𝑐𝑚𝑐𝑜𝑟𝑒
(1 − 𝑤𝑐)𝜀𝑐𝑥𝑠
  (3.1) 
Where wc [%wcoating/wuncoated cores] is the coat weight, mcore [g] is the mass of uncoated cores, εc [-
] is the mass efficiency of the process, xs [%wsolids in suspension/wsuspension] is the fraction of solids in 
suspension and msuspension [g] is the coating suspension to be applied. The coating suspension was 
continually stirred throughout the coating process. 
3.3.5 Curing 
Preliminary studies showed no significant changes to the dissolution profiles of coated material 
(results not shown) after being cured at 40 °C and 75% relative humidity for 16 hours. From these 
results, it was inferred that these conditions should promote stable film and adequate curing conditions. 
Each batch was divided into two sub-sample sets. One of the subsamples was subjected to a curing step 
at 40 °C and 75% relative humidity for 16 hours in a stability chamber.  Both uncured and cured 
subsamples were kept refrigerated at 4 °C in amber glass bottles while held for further characterization.  
3.3.6 Dissolution testing  
The equivalent of 100 mg API was subjected to release testing using the USP/Ph.Eur 
dissolution Apparatus II (paddles), rotational speed 100 rpm, 900 mL of 50 mM potassium phosphate 
buffer, pH 6.2 (Chata Biosystems, USA), N=3. The detection was done by UV-VIS at 320 nm with 
baseline correction at 380 nm using dip style probe (Pion, USA) with a 1 cm cell path length collecting 
120 spectra every 30 sec for 120 minutes. 
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3.3.7 Film thickness 
Following the mounting procedure for EpoxyCure2 (Buehler, USA), it was possible to entrap a 
portion of cured microspheres in an epoxy mold. After 6 h to 10 h hardening, the microsphere-epoxy-
puck was sanded with a 240 grit sandpaper until the microspheres were exposed at the surface followed 
by 360 and 600 grit sandpapers and MetaDi II 3 and 1 μm diamond paste (Buehler, USA) to smooth 
the surface. The surface was then analyzed by a polarized light microscope Leica DMRX-POL (Leica 
Microsystems Wetzlar GmbH, Germany) to measure the thickness of the coating on five microspheres 
(per puck) on an average of six locations per microsphere. An average of the six locations results was 
used for this analysis. 
3.3.8 Data analysis software 
Results from dissolution tests, i.e. amount of API released at 30, 60, 90 and 120 min were used 
as response variables for data analysis of variance (ANOVA). The software used to assess the 
influence of the main factors under study on taste masking was Design Expert® version 8.0.1 (Stat-
Ease, Inc. Minneapolis, MN, USA).  
3.3.9 Surface area analysis 
Nitrogen adsorption isotherms at 77 K were measured in an accelerated surface area and 
porosimetry system (ASAP 2020) (Micromeritics, USA). Cured samples were previously degassed at 
30 °C in order to preserve their integrity, under vacuum (3 μmHg) for 72 hours.  Specific surface area 
was calculated using Brunauer-Emmett-Teller (BET) equation using 0.14 to 0.30 P/P0 adsorption 
values range[112]. 
3.3.10 Scanning Electron Microscopy 
Scanning Electron Microscopy (SEM) (S-4700, Hitachi, USA) was used to investigate the 
microstructure of the coating on three microsphere cross-sections at different locations. Each of the 
analyzed pucks (prepared as per section 3.3.7 Film thickness) was sputtered with gold-platinum using 
argon in a partial vacuum chamber. SEM images were obtained at an acceleration voltage of 5.0 kV. 
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3.4 Results and Discussion 
3.4.1 ANOVA of MSC coated microspheres dissolution for 30, 60, 90, 120 min. 
Uncured 
The DoE was used to estimate the magnitude and direction of the main effects on the 
percentage of API released at 30, 60, 90 and 120 min from MSC microspheres coated with 
Kollicoat®Smartseal 30D at pH 6.2 for uncured microspheres. As the DoE was a screening design with 
a limited number of experimental conditions, higher order interactions were not considered. Using the 
data generated from the DoE batches to fit the overall model (Table 3.1), the critical formulation and 
process parameters on final performance were estimated by means of analysis of variance (ANOVA). 
ANOVA for main factors is presented in Annexe II. The analysis was conducted taking into 
consideration that effects with a p-value less than 0.05 give an indication that the term is 
significant[83]. 
Table 3.1 Model factor of ANOVA analysis of average dissolution responses at pH 6.2 of uncured microspheres for 30, 60, 
90, and 120 min. 
 30 min 60 min 90 min 120 min 
 
Estimated model factor in terms of actual factors (not coded) 
(p-value) 
Intercept 140.6 137.3 132.5 127.1 
Coating Level 
(%w/w) 
-2.4 
(<0.0001) 
-2.0 
(<0.0001) 
-1.8 
(<0.0001) 
-1.5 
(<0.0001) 
Plasticizer Level 
(%w/wdry polymer) 
-3.4 
(<0.0001) 
-2.5 
(<0.0001) 
-2.0 
(<0.0001) 
-1.6 
(<0.0001) 
Atomizing Air Pressure 
(bar) 
4.4 
(0.0025) 
4.8 
(0.0002) 
4.8 
(0.0002) 
4.5 
(0.0002) 
The ANOVA results show that the coating level, plasticizer level and atomizing air pressure all 
have a statistically significant effect on the percentage of API released. The other factors were not 
found to have a statistically significant effect within the studied levels. Let us therefore discuss these 
three factors in turn. 
The coating level is an indirect measurement of the coating thickness being applied to the 
microspheres, which explains its impact: a higher coating level implies a thicker barrier membrane and 
more complete coating coverage across the batch which translates to the dissolution being suppressed 
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at pH 6.2. Figure 3.2 shows the clear effect of coating level for the API release from MSC 
microspheres coated with Kollicoat®Smartseal 30D at pH 6.2. 
 
Figure 3.2 Percentage of API released as a function of time for representative coating weight gain: 0% w/w (uncoated 
microspheres, solid black line), 7.00% w/w (batch 20, dash-dotted orange line), 15.3% w/w (batch 2, dashed teal line) and 
23.6% w/w (batch 17, yellow dotted line) for uncured coated microspheres with Kollicoat®Smartseal 30D at pH 6.2. Each 
point represents mean ± standard deviation calculated from three subsamples of each batch. 
At the same coating level, variations of around 6.0% (for the lowest coating level, 7% w/w) 
and 22% (for the highest coating level, 23.6% w/w) were measured in release of API at 60 min of 
dissolution. Indicating that other parameters, besides coating level, may be influencing the API release. 
As the ANOVA model indicates, we also have to take into consideration the effect of plasticizer levels 
and atomizing air pressure. 
The level of plasticizer used had a negative impact on API dissolution. That is to say that the 
amount of API released is greatest at lower plasticizer concentrations. For example, at 60 min the 
average percentage of API released for the lower level of plasticizer (12% w/wdry polymer) was 83% and 
was 60% at the higher level of plasticizer (20% w/wdry polymer). The percentage of plasticizer is 
calculated in relation to the dry polymer content in the suspension, meaning that an increase in 
plasticizer level corresponds to an increase of the plasticizer to polymer (film former) ratio. Higher 
levels of plasticizer give the polymer chains more elasticity[28] and facilitate the coalescence of 
discrete polymer particles, favoring a more complete film formation. 
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Higher atomizing air pressures lead to smaller droplet sizes, which in turn lead to a more 
uniform coating being applied and lower API release[70]. However, the model shows that the 
atomizing air pressure seemed to cause an unwanted increase in API release. When analyzing the batch 
records, results show that batches with an atomization pressure of 3 bar had a mass coating efficiency 
on average lower (79.4%) than for batches with atomization pressure of 1 bar (91.1%). This seems to 
indicate that some proportion of the spray dried prematurely for batches with higher atomizing air 
pressures, possibly resulting in less polymer being applied to the microspheres than anticipated, which 
would lead to increased API release. 
Cured 
The overall estimated model results of cured microspheres from release studies at 30, 60, 90 
and 120 min (Table 3.2) show the effect of curing on critical formulation and process parameters on 
final performance. Curing decreases the overall percentage of API dissolved. After curing the average 
percentage of API released at 60 min is approximately 32% when compared to 72% before curing.  
Table 3.2 Model factor of ANOVA analysis of average dissolution responses at pH 6.2 of cured microspheres for 30, 60, 90, 
and 120 min. 
 30 min 60 min 90 min 120 min 
 
Estimated model factor in terms of actual factors (not 
coded) 
(p-value) 
Intercept 96.8 118.1 163.1 167.6 
Coating Level 
(%w/w) 
-3.1 
(<0.0001) 
-3.9 
(<0.0001) 
-4.1 
(<0.0001) 
-4.3 
(<0.0001) 
Plasticizer Level 
(%w/wdry polymer) 
-2.6 
(<0.0001) 
-2.8 
(<0.0001) 
-2.9 
(<0.0001) 
-2.7 
(<0.0001) 
Spray Rate 
(g/min) 
1.6 
(0.03) 
1.9 
(0.01) 
2.3 
(0.001) 
2.2 
(0.0004) 
Product Bed 
Temperature (°C) 
- - 
-1.3 
(0.03) 
-1.3 
(0.01) 
For cured samples, the main effects controlling drug release are the coating level, plasticizer 
level, spray rate and product bed temperature. The reason why coating level and plasticizer  impact the 
percentage of API at the studied times has already been discussed in the previous section. Unlike 
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uncured samples (Table 3.1), atomizing air pressure was not found to be significant. Note that the 
uncured film cast onto the microspheres is not yet in its final form and as such the stability of the 
coated dosage form is compromised. Caution should be taken when drawing conclusions using the 
uncured dissolution data as a response variable, because of the transient nature of the uncured coated 
microspheres. Nevertheless, the comparison between uncured and cured dissolution profiles comes to 
confirm the importance of curing for complete film formation when coating with aqueous 
suspension[63].  
 
Figure 3.3 Percentage of API released as a function of time for representative coating weight gain: 0.00% w/w (uncoated 
microspheres, solid black line), 7.00% w/w (batch 20, dash-dotted orange line), 15.3% w/w (batch 2, dashed teal line) and 
23.6% w/w (batch 17, yellow dotted line) for cured coated microspheres with Kollicoat®Smartseal 30D at pH 6.2. Each point 
represents mean ± standard deviation calculated from three subsamples of each batch. 
Figure 3.3 shows the effect of coating levels for the API release from MSC microspheres at pH 
6.2 of cured coating. When comparing Figure 3.2 and Figure 3.3 it is observable that for the same coat 
weight gain, the percentage of API released at a given time decreases significantly after curing. These 
results clearly indicate that at the end of the coating process the polymeric film is not fully formed. By 
exposing the coated microspheres to higher temperatures (after coating) the fusion of neighboring 
polymeric particles[105] is promoted, allowing the polymeric coating particles to coalesce and form a 
more compact film around the microsphere. This phenomenon may explain why atomization air 
pressure is no longer a critical factor, as the spray dried droplets might partially coalesce during curing 
which would in turn decrease the effect of atomization air pressure seen in the uncured samples. 
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At increased spray rates the percentage of API released increases. The inverse effect was 
observed for product bed temperature. This is to say, lower product bed temperatures resulted in higher 
percentage of API being released. In both cases (higher spray rates and lower product bed temperature) 
the resulting microsphere should have higher residual moisture. It has been previously reported by 
Williams III, et al.[113]  that product bed temperature and spray rate have influence film formation 
during curing. 
The accepted mechanism for film formation when using aqueous polymer dispersions is that 
after the spraying of the aqueous polymer dispersion onto the microspheres’ surface, water evaporates 
and the polymeric particles deform and approach leading to coalescence[105]. Dry sintering and 
capillary forces are pointed as possible drivers for coalescence[113], [114]. Higher water content in the 
microspheres generally promotes film coalescence, leading to continuous and well-packed films. 
However this is the inverse effect of what is observed in this case. It has also been reported that higher 
spray rates and lower temperatures can produce cracks in the film[114]. Solvent loss beyond the 
solidification point can cause shrinkage of the coating and subsequently contribute for the internal 
stress within a coating and the formation of cracks[115], which could potentially be the explanation for 
the appearance of spray rate and product bed temperature as significant factors after curing. 
It has been shown that curing promotes complete film formation[105], [106], [116], [117], 
nevertheless the initial number of polymeric layers still plays an important role on the percentage of 
API release, so much so that, for particles coated with a low number of layers (lower coat weight gain) 
there is a considerable amount of drug release even after curing. 
3.4.2 Thickness and surface area impact on dissolution of cured microspheres 
As discussed previously, the amount of coating applied onto the microspheres will act as a 
diffusion barrier and prevent the API from being released into the oral cavity[62], explaining why 
thickness is considered a critical quality attribute for the coating process. The mean coating thicknesses 
of the cured microspheres ranged from approximately 4.2 μm to 19 μm between batches. In Figure 3.4, 
as expected, thicker coatings released less when compared to thinner coatings. However, there are still 
variations in terms of release profiles between batches that have similar coat weight gains (or 
thicknesses). Given the lengthy sample preparation time for specific surface analysis measurement, it 
was chosen to sample across the DoE and only measure a few critical samples, which is why not all 
batches have a measured surface area in Figure 3.4. 
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Figure 3.4 Effect of thickness on percentage of API released from cured MSC coated microspheres with Kollicoat®Smartseal 
30D at 50 mM potassium phosphate buffer pH 6.2 at 60 min. Color code based on the results of surface analysis: red are 
batches with high surface area (≥0.1 m2/g), in green with low surface area and in black are points where surface area was not 
measured. 
Specific surface area is the total surface area of a material per unit of mass (or volume). An 
increase in particle size (due to coating) corresponds to a decrease in specific surface area. It is 
interesting to look at the specific surface area because it gives insight on how a solid interacts with its 
surroundings. In this case it clarifies how microspheres might interact with the dissolution media and 
help hypothesize on the structure of the coating. In the case of non-uniform or highly porous coating 
layers (and the MSC microsphere core) the specific surface area exposed to the dissolution media is 
higher. If there is higher specific surface area exposed, higher amounts of API will be dissolved for the 
same amount of time, because as it was first described by Bruner and Tolloczko[118], the dissolution 
rate is directly proportional to the surface area of the undissolved solid in contact with the solvent. As 
such, for porous coating layers (high specific surface area) the probability that continuous dissolution-
media-filled channels exist is higher[116], [119] than for non-porous coating layers (low specific 
surface area). 
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In Figure 3.4 one can see that for batches with similar levels of coating thickness, the ones that 
release the least also had a lower specific surface area. A hypothesis that would help us explain this 
phenomenon would be that when comparing batches with the same thickness the high specific surface 
area batch should present a more porous (or non-uniform) coating than the one presenting low specific 
surface area. Analyzing SEM images of coatings with similar thicknesses but significantly different 
surface areas helped us to qualitatively (visually) confirm this hypothesis. A comparison was made 
between average batches, batch 16 (19±0.8 µm, high surface area) and batch 17 (16±2 µm, low surface 
area), with batches that have thicker coatings, batch 1 (9.6±2 µm, high surface area) and batch 2 (10±1 
µm, low surface area) as well as with batches which have thinner coatings, batch 13 (4.2±0.3 µm, low 
surface area) and batch 12 (6.3±2 µm, high surface area). SEM images are shown in Figure 3.5 (for 
clarity the reader is advised to consult the online version of this document). 
For batches 16 and 17, where a thicker coating was applied, given the higher percentage of API 
dissolved and specific surface area of batch 16, it was expected to have a highly porous film when 
compared to batch 17. In Figure 3.5 (A) (batch 16) one can see that the coating presents more cracks 
than in Figure 3.5 (B) (batch 17). Aligning these observations with the ANOVA results from the 
previous section it was verified that in batch 17 a higher amount of plasticizer was used (20% w/wdry 
polymer) than for batch 16 (12% w/wdry polymer). 
When compared to batches 1 and 2, coating thickness is approximately the same 
(approximately 10 µm). As can be observed in Figure 3.5 (C) and (D), the surface of the coating in 
batch 1 is more irregular than in batch 2, thus implying a more porous coating. Interestingly, in batch 1, 
the atomizing pressure was of 3 bar, versus 2 bar in batch 2. Figure 3.5 (C) seems to suggest that the 
coating spray dried prematurely, given that the structure of the droplets is still present even after 
curing. A layer of coating is applied with several passes through the spray, in order to produce 
complete coverage of the surface (layering)[46]. Mechanisms known to lead to layered particle growth 
include the agglomeration of semi-dried droplets on particle surface[120], a phenomenon that may 
have happened under batch 1 conditions as higher atomizing air pressures resulted in smaller spray 
droplets that dried before reaching the core[50].  This is in agreement with the conclusions from the 
ANOVA analysis of uncured microspheres dissolution, when it was verified that atomizing air pressure 
caused an increase in API release.  
Batch 13 seemed like a particularly interesting batch to analyze because an extremely thin 
coating was applied (4.2±0.3 µm) and a relatively low API release at pH 6.2 when compared to the 
thicker coatings (31% API released at 60 min). As such, a non-porous coating layer was to be expected 
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for batch 13 (low surface area) when comparing it to batch 12 (97% API released and high surface 
area), especially when considering that in batch 13, a higher amount of plasticizer was used (20% 
w/wdry polymer) than for batch 12 (12% w/wdry polymer). Additionally, when looking at the SEM images and 
the thickness values standard deviation (0.3 µm), it seems that the coating applied to batch 13 was thin 
but uniformly applied onto the surface of the coated microsphere (Figure 3.5 (F)). Batch 12 (6.3±2 µm) 
has higher variability of coating thickness (a higher standard deviation) and from the SEM, it seems 
that the coating did not cover the whole microsphere Figure 3.5 (E). However, the authors consider that 
the SEM results were inconclusive as the coating is too thin and it was not possible to clearly 
differentiate the coating structure. 
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Figure 3.5 SEM images of a cross section of cured coated microspheres (A) Batch 16, mean coating thickness = 19±0.8 µm 
(B) Batch 17, mean coating thickness = 16±2 µm (C) Batch 1, mean coating thickness = 9.6±2 µm (D) Batch 2, mean coating 
thickness = 10±1 µm. (E) Batch 12, mean coating thickness = 6.3±2 µm and (F) Batch 13, mean coating thickness = 4.2±0.3 
µm. False color was added to highlight the different regions in the images, color scheme is as follows: Blue: epoxy, orange: 
coating, yellow: MSC microsphere core. 
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3.5 Conclusion 
This research aims at understanding how the coating process using a reverse enteric polymer 
(Kollicoat®Smartseal 30D) can be used to facilitate the development of pediatric formulations 
designed to overcome one of the major limitations with current pediatric medications, poor palatability. 
The significance of the studied variables on the amount of API released in simulated saliva, 
which is a surrogate for taste masking, was evaluated by ANOVA. Results from this study indicate that 
within the chosen design space, out of seven key variables, atomizing air pressure, coating level and 
plasticizer levels are the critical process parameters and critical material attributes to be controlled for 
optimal taste masking. However, once the coated material is submitted to curing, the only remaining 
critical process parameters are coating level and percentage of plasticizer with the appearance of spray 
rate and product bed temperature. Indicating that curing is a crucial part of the process for this polymer 
system as it allows for a complete film formation and reduces overall variability within the batch. In 
future work, it would be important to understand the fundamental mechanisms behind the curing step 
in order to facilitate the formulation, development, choice of an adequate coating level and understand 
the role of relative humidity to the curing process. 
It was also shown that even though coating thickness helps to explain the majority of the 
variation in coating performance, the coating microstructure also has an important impact on 
dissolution. BET analysis and SEM were used to characterize the microstructure of the coating, 
showing that in the future porosity should be considered as a critical quality attribute. Even for low 
specific surface areas, BET analysis using N2 adsorption can still provide a useful qualitative 
measurement regarding the surface area of the microspheres. For the present study, SEM was used to 
visually confirm how the qualitative differences in specific surface area impact coating structure and its 
effect on dissolution. Future work in this area should include investigations on quantitative 
characterization of the porosity of the coatings being applied, as well as the influence of key variables 
on the porosity to gain a better control on the impact of the porosity on the critical quality attributes.  
Future work in this field should also include the understanding of the API release mechanism 
of the Kollicoat®Smartseal 30D coated microspheres, not only at pH 6.2 (to evaluate the API release 
in the mouth), but also at lower pHs in order to simulate gastric conditions, as a surrogate test to ensure 
bioavailability. 
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Contributions to the thesis: In the previous chapter the criticality of coating thickness and 
coating microstructure for the in-vitro API dissolution at pH 6.2 were demonstrated. Therefore, 
monitoring fluid bed coating operation is of crucial importance in order to ensure consistent coating 
performance. This chapter provides a methodology that allows a one-to-one comparison between three 
different PAT tools, process data and raw material attributes in order to be able to recommend a 
process monitoring strategy that could in the future facilitate the development of a control strategy. 
Work was carried out on a bench-scale fluid bed coating unit (GPCG-2) where the window of the unit 
was replaced by a PAT adaptor able to accommodate multiple PATs simultaneously. Results show that 
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in-line Raman spectroscopy has a superior predictive performance (even better than process data) to 
monitor the coating process. 
Titre en français : Suivi du procédé d’enrobage des microsphères par outils PAT 
Résumé en français:  
Parmi les facteurs qui influencent l’acceptation de la médication dans la population 
pédiatrique, le goût et l’irritation ont été identifiés comme des obstacles critiques pour l’adhésion 
thérapeutique des patients. Afin d’améliorer cette adhésion, les microsphères (systèmes matriciels dans 
lesquels le médicament est dispersé) peuvent être enrobées avec un polymère entérosoluble inverse qui 
empêche la libération de médicament dans la cavité buccale mais maintient une libération immédiate 
lorsque le médicament atteint l’estomac, et ce, dans le but d’obtenir un profil neutre pour le goût. Dans 
le cadre de ces travaux, la performance en ligne de trois technologies d’analyse des procédés (PAT) a 
été évaluée pour suivre le procédé d’enrobage des microsphères. Ces technologies sont la spectroscopie 
Raman, la spectroscopie proche infrarouge (near infrared : NIR) et la mesure de la réflectance du 
faisceau focalisé (focused beam reflectance measurement: FBRM), avec les données du procédé et les 
caractéristiques des matières premières. La performance des différentes sources d’information pour 
prédire les performances de la barrière d’enrobage est évaluée en utilisant une approche combinée des 
données : multiblock partial least squares (MBPLS). Les résultats montrent que la spectroscopie 
Raman a une performance de prédiction supérieure et qu’elle peut permettre de suivre le procédé 
d’enrobage des microsphères ainsi que de détecter les écarts par rapport au procédé, démontrant son 
utilité pour suivre l’enrobage par lit d’air fluidisé. Ce suivi est considéré crucial pour assurer la 
performance continue d’un enrobage par des membranes bloquantes composées de films fins. 
Mots clefs : spectroscopie proche infrarouge, spectroscopie Raman, mesure de la réflectance 
du faisceau focalisé, MBPLS, enrobage dans un lit d’air fluidisé avec Wurster 
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4.1 Abstract 
Among the factors that influence adherence to medication within the pediatric population, 
taste/irritation has been identified as a critical barrier to patient compliance.  With the goal of 
improving compliance, microspheres (matrix systems within which the drug is dispersed) can be 
coated with a reverse enteric polymer that will prevent the release of the drug in the oral cavity while 
maintaining an immediate release once the drug product reaches the stomach, thereby achieving a taste 
neutral profile. In this work, the in-line performance of three process analytical technology (PAT) tools 
is evaluated in order to monitor the microsphere coating process. These tools are Raman spectroscopy, 
near-infrared spectroscopy and focused beam reflectance measurements, together with process data and 
raw material attributes. The ability of these different sources of information to predict the coating’s 
barrier performance is evaluated by using a combined-data-approach: multiblock partial least squares 
(MBPLS). Results show that Raman spectroscopy has had a superior predictive performance and that it 
has the potential to monitor the coating process of the microspheres as well as to detect process 
discrepancies (such as spray rate changes), demonstrating its usefulness for the monitoring of fluid bed 
coating processes. It was also demonstrated that Raman can also be used to clearly differentiate batches 
with significantly different in-vitro dissolution performance. This monitoring is considered critical to 
ensure consistent coating performance for this thin film barrier membrane that is essential to patient 
compliance. 
Key words: NIR, Raman, FBRM, MBPLS, Wurster coating 
4.2 Introduction 
Due to its convenience, the oral route is the preferred route of drug administration both for 
adults and children[17]. Taking into consideration the span of the pediatric population, it is desirable to 
design a dosage form that can provide the necessary dosage flexibility and overcome a limitation for 
pediatric patient compliance: the bitter (and sometimes burning[107]) taste of active pharmaceutical 
ingredients (API)[13]–[15]. Microspheres have been pointed out in the literature as a possible 
solution[14], [17]. In this work, microspheres were produced by the use of melt-spray-congeal (MSC), 
a continuous manufacturing process that produces highly spherical particles with a narrow particle size 
distribution [121].  
Reverse enteric polymer(s) are cationic polymers with amino groups[122] that are less water 
soluble at neutral pH than at acidic pHs[32]. This property makes them ideal for taste masking 
applications, given that saliva pH is generally in the range of 6.2 to 7.6[64] and gastric pH for fasted 
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state is pH 1 to 2[104], thus ensuring  that the drug will release upon exposure to acidic environment 
while minimizing release in the oral cavity. It should be noted that gastric pH can vary with food 
intake, pathophysiological conditions and concurrent drug therapy (such as proton pump 
inhibitors)[104]. 
Like other SODs, microspheres can also be coated to guarantee patient compliance. When 
coating small particles, Wurster coaters are a popular unit operation within the pharmaceutical 
industry[58]. For further details on the Wurster coating process, the reader is advised to see section 2.4. 
For further information on fluid bed coating with Wurster insert process, an overview of the 
macro[62]- and micro[70]-level processes was compiled by Werner et al. In a typical setting, the 
particles get coated by successive passes through the Wurster insert until the desired coat weight gain 
is achieved. The mass of coating deposited onto the microspheres has a direct impact on the thickness 
of the coating, and as such on its biopharmaceutical performance[123], [124].  Even though a direct 
measurement of the coating thickness would be desirable, the most common approach is to measure the 
coating solution/suspension weight loss[125] to determine the endpoint of the process, which does not 
necessarily provide information regarding coating uniformity or thickness (as the mass coating 
efficiency of the coating process will always be inferior to 100%, due to spray mass coating losses). 
Additionally, in order to promote adequate coating coalescence of the polymeric particles and efficient 
control of process parameters (fluidization, atomization and drying), film coating composition and 
curing needs to be ensured[47].  
In past years, the paradigms of pharmaceutical and bio-pharmaceutical manufacturing have 
been changing. Examples of this are the United States Food and Drug Administration’s application of 
the process analytical technology (PAT) guidance[24] and the use of the quality by design (QbD) 
approach by the International Conference on Harmonization[21], [82]. Linking product quality to the 
desired clinical performance allows to design a robust formulation and process to consistently deliver 
the desired product quality[80]. Traditional methods of monitoring the critical quality attributes are 
typically limited to either endpoint analysis or infrequent sample collection. With the implementation 
of PATs, the goal is to achieve real-time analysis of the process via in-line monitoring. For PAT 
applications, it is necessary for the analytical results to be available immediately in order to facilitate 
real-time decision making[81]. A systematic understanding of the coating process is required for the 
development of new products to be consistent with the PAT initiative[21], [24], as PAT process 
analyzers can bring many benefits in design, evaluation and control of film coating processes. 
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Knop and Kleinebudde[125] and more recently Korasa and Vrečer[126] have provided a 
thorough review of PATs in pharmaceutical film coating application as tools to monitor coating 
process critical quality attributes. Korasa and Vrečer[126] explicitly divided the above mentioned 
PATs by solid oral dosage form (either tablets or microspheres), highlighting that both near-infrared 
(NIR) and Raman are the most widely used process analyzers in film coating. However, in most works 
described in the literature for monitoring microsphere coating, only one PAT is evaluated at a time. 
The exception seems to be the work of Bogomolov et al.[127] where both NIR and Raman 
spectroscopy were compared based on the performance of the individual and combined (NIR and 
Raman) spectroscopic tools. In this work, three PATs were investigated: NIR, Raman and Focus Beam 
Reflectance Measurement (FBRM). 
A molecule is NIR active when induced vibrational change results in change of the molecule’s 
dipole moment. Typically, vibrational combinations and overtones of carbon-hydrogen, nitrogen-
hydrogen and oxygen-hydrogen bonding produce NIR signatures. Interactions between atoms in 
different molecules alter vibrational energy states, thereby shifting existing absorption bands and 
giving rise to new ones, through differences in structure, which explains why NIR spectra contain 
information on the chemical composition as well as the physical information (such as particle 
size)[128]. This renders NIR spectroscopy unselective, as it is influenced by a number of physical, 
chemical and structural variables. Multivariate data analysis has helped to extract relevant information 
from the data. Anderson et al.[129] were the first to demonstrate the feasibility of quantitative in-line 
of film coating on pellet monitoring using NIR spectroscopy by use of the concept of multivariate 
batch calibration. Another good example of NIR being used to develop models to predict 
multiparticulates’ performance is the work by Avalle et al.[123], where for a multiple-layer 
multiparticulate Partial Least Squares (PLS) models were developed to (a) determine the thickness of 
the API layer, (b) the API loading, (c) the functional coating thickness and (d) the release profile of 
80% of the drug. 
Raman spectroscopy involves a change in the electronic polarizability of the molecule[130] by 
irradiation of a sample with monochromatic light in the visible and NIR region and detection of the 
scattered light. Raman spectroscopy is often seen as complementary to NIR, as it allows the analysis of 
solids in the presence of water[125]. In contrast to infrared absorption, which is associated with polar 
molecules, Raman spectroscopy is associated with polarizable, delocalized electronic systems. 
Aromatic or conjugate structures, for example, produce strong Raman scattering[126]. Raman 
spectroscopy has many of the same advantages as NIR: non-destructive, high acquisition rate, minimal 
to no sample preparation and versatility. However attention should be paid to natural fluorescence, 
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which can cause interferences and potentially mask the Raman spectrum[124]. Works like the one 
develop by Hisazumi and Kleinebudde[131] in which the authors compared multiple curve resolution 
to PLS regression demonstrate the usefulness of Raman to determine (in-line) the film thickness of 
multi-layered pellets. 
FBRM estimates chord length, which is defined as a geometric line segment whose endpoints 
lay on opposite edges of the particle under analysis. FBRM relies on measuring the light that is 
reflected back through the probe when a focused rotating laser beam hits a particle. The chord length is 
calculated by multiplying the duration of the reflection and the laser scan speed[132]. By measuring 
several particles (at random locations of the particles), a chord length distribution can be estimated, 
which corresponds to the number of times a given chord length was measured in the form of a 
probability density function. FBRM has successfully been applied to monitoring in-line particle growth 
in the granulation process in fluidized bed[133]. Most works evaluate FBRM in fluid bed granulation 
in comparison to traditional off-line technologies[132]. There is still very little research done in the 
field of In-line particle size measurement for coating process evaluation of coating thickness and the 
(in this case) undesirable tendency of agglomeration and/or attrition. It is however relevant to mention 
the work of Folttmann et al.[134] where spatial filtering velocimetry (another chord length distribution 
technique) showed reliable results to predict particle growth for the fluid bed coating process.  Kukec 
et al.[135] performed an in-line comparative study between FBRM and spatial filtering velocimetry 
probe for monitoring the kinetics of particle growth in fluid bed melt granulation process. They were 
able to demonstrate the efficacy of both probes to predict process end-point. 
In the present work, three PAT tools (NIR, Raman and FBRM) were installed on a bench-top 
Wurster fluid bed to monitor the coating process of MSC microspheres in real time. This work seeks to 
evaluate and compare strategies to monitor temporal variations of the fluid bed with Wurster insert 
bench-scale process of microsphere coating. The analysis is made by combining these PAT sources of 
information with the process and raw material data in order to predict the coating thickness and the 
API dissolution performance, based on multiblock partial least squares (MBPLS). From the model 
coefficients for each block and the block importance for prediction (BIP)[93], the usefulness of each 
data source can be established, making it possible to classify batches into within/outside product 
specifications categories and understanding the differences between process trajectories that lead to 
this variability. 
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4.3 Materials and Methods 
4.3.1 Making microspheres and coating runs 
In order to avoid redundancy the reader should refer to:  
 Sub-section 3.3.1. Microspheres manufacturing, where the process of manufacturing 
microspheres and the materials used are described; 
 Sub-section 3.3.2 Preparation of coating suspension; 
 Sub-section 3.3.3 and 3.3.4 for a description of the coating process. Each batch was 
controlled to maintain the inlet airflow, the product bed temperature, as well as the 
spray rate and atomizing air pressure within the levels of the DoE (see Annexe I) in 
order to achieve the target coat weight gain by using the calculated coating suspension 
consumption. Note that due to Raman robustness issues it was not possible to monitor 
all 21 batches, batches 10 to 13 were excluded from the following analysis. 
Given that coat weight gain, spray rate and solids in suspension were all parameters of the 
DoE, the duration of the batches was variable and spanned from 20 min to three hours. Process 
parameters were recorded manually at a frequency of 5 min until the desired suspension coat weight 
loss was achieved.  
After coating, the samples were cured for 16 h at 75% relative humidity at the temperature of 
40 °C in a stability chamber, like described in sub-section 3.3.5.  
4.3.2 PAT data acquisition 
In order to fit the PAT tools into the GPCG-2 fluid bed, an adaptor was custom-built to be 
interchangeable with the fluid bed equipment window (Figure 4.1), minimizing the modifications that 
needed to be made to the unit. The adaptor has five positions where the PATs can be mounted onto the 
fluid bed, each position being approximately 6 cm apart (center to center). The probes were inserted 
perpendicularly to the lateral surface of the product bed and the probe tip was flush mounted to the 
inner wall of the fluid bed in order not to disrupt the microsphere flow (Figure 4.1 C). 
There was an initial effort to optimize the data quality by studying the impact of different 
positions and acquisition time on the PATs signal. The positions sought to reduce the noise in the 
spectra and maximize the number of counts. Initial tests showed that Raman signal was the least 
affected by position, not exhibiting significant differences between the three positions (counting from 
the base of the product bowl). The number of counts with FBRM was stable between positions one and 
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two, but then significantly decreased when the probe was inserted in position three. NIR signal was 
greatly affected by the positioning of the probe; the signal to noise ratio decreased when this probe was 
inserted in position number 2 from the bottom of the product bowl. For this reason the final 
configuration used throughout this study was NIR at the bottom position of the adaptor, position one, 
followed by FBRM in position two and finally Raman in position three (counting from the base of the 
fluid bed). The two other available positions were unused and kept close with a cap. 
 
Figure 4.1 3D model of (A) Top view of (B)Product bowl of Glatt GPCG-2 with PAT window adaptor and the 3 PATs: NIR 
in position one, FBRM in position two and Raman in position three counting from the bottom. (C) Illustrative schematics of 
particle (in orange) movement (white arrows) inside the fluid bed. 
The FBRM® D600 (Mettler Toledo, USA) chord length distributions were estimated using 
icFBRM (Mettler Toledo, USA) software that controlled the data acquisition rate at every 10 seconds 
(integration time set at 10 s).  
The NIR ePAT611 (Expo Technologies LLC, USA) integration time was 25 milliseconds, the 
recorded spectra rate was 125 milliseconds. Each recorded spectra was an average of five spectra. NIR 
was controlled by the NovaPAC software (Expo Technologies LLC, USA). The spectral range was 
collected between 1096 nm and 2103 nm with a 4 nm spectral resolution.  
The Pro-Raman Process Analyser (TSI, former ENWAVE Optronics, Inc., USA) was 
controlled by Symbion DX& RX suite (Symbion Inc., USA) to have a spectral acquisition every five 
seconds (integration time set at 5 s). The spectral region collected ranged from 250 cm-1 to 4428 cm-1 
with a 2 cm-1 spectral resolution. 
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4.3.3 Reference methods 
Thickness 
To obtain a clear image of the cross-sections of the microspheres, these were entrapped in an 
epoxy mold, following the preparation procedure and analysis stated in sub-section 3.3.7. The 
measured coating thicknesses varied between 6.6 µm and 19 µm, between the 17 batches. 
Dissolution testing 
The dissolution testing at pH 6.2 methodology is detailed in sub-section 3.3.6. For the 17 
batches, the average of the three replicas at 120 min was used to build the models, which varied 
between 0 and 97.6% of API released. 
4.3.4 Summary of data  
Figure 4.2 summarizes monitored variables that are descriptive of the process. The variables 
were classified in two groups: raw material and temporal variables. Raw materials are discrete 
variables set at the beginning of the process, while temporal variables are measured over the entire time 
history of the batch. A reminder of the nomenclature used: vectors are indicated by bold lower-case 
characters, two-way matrices by bold capitals and finally underlined bold capitals for three-way arrays. 
 
Figure 4.2. List of variables monitored during the coating runs. 
Temporal data 
Coating suspension weight 
Spray rate 
Product bed temperature 
Inlet air temperature 
Inlet airflow 
Atomizing air pressure 
Exhaust air humidity 
Exhaust air temperature 
Differential filter pressure  
Differential bottom screen 
pressure 
Process 
NIR 
Raman 
Spectral data 
Initial mean diameter of the 
particles 
Uncoated mass of 
microspheres 
% of polymer in suspension 
% of plasticizer in suspension 
% of antioxidant in 
suspension 
% of anti-static in suspension 
%of anti-tacking 
Initial pH coating suspension 
Raw material properties 
Particle size 
FBRM 
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The temporal data can thus be divided in four 3D matrices, Process (P), NIR (N), Raman (R) 
and FBRM (F) data, each with dimensions [batches × variables × time]. 
The selected wavelength for analysis in the NIR data ranged from 1136.8 nm to 1933.4 nm 
(202 data points), Raman ranges from 906 cm-1 to 1636 cm-1 (366 data points) and FBRM ranged from 
1 µm to 331.13 µm (85 data points). Other regions were excluded from the analysis because they were 
uninformative or noisy. 
Several data pretreatment methods were applied to the spectra, with the best results for NIR 
data obtained with a combination of standard normal variate (SNV, usually used for scatter 
correction)[136], followed by Savitzky-Golay estimate of the second derivative using 15 points and a 
first order polynomial (used to offset additive plus multiplicative effects)[136].  For Raman data, SNV 
alone was needed and FBRM required SNV and 15 point smoothing in order to normalize the 
differences induced by variations in air flow across the DoE.  
In order to align/synchronize the batches that had different duration and the different sources of 
temporal variables that had different acquisition rates, the time series of all variables were linearly 
interpolated[137] by resizing the data from 0 to 100% batch completion.  
As such, for the temporal data, the geometry dimensions of the four final matrices are P [17 × 
10 × 100], N [17 × 202 × 100], R [17 × 366 × 100] and F [17 × 85 × 100]. The Raw material properties 
matrix (M) has dimensions of [17 × 8] and finally the reference (thickness and percentage of API 
released at pH 6.2 at 120 min) were treated as two separate vectors [17×1]. These last two vectors were 
mean-centered and divided by their standard deviation. 
4.3.5 Multiway data unfolding 
The original three-way data must be reshaped into a two-way array, also known as 
“unfolding”[91]. Unfolding is needed in order to perform the standard two-way principal component 
analysis (PCA) as well as the partial least squares (PLS) and multiblock PLS regression models.  Two 
unfolding methods will be described here: batch wise unfolding (BWU) and observations wise 
unfolding (OWU). 
BWU (Figure 4.3) is an unfolding technique that emphasizes the differences between 
individual batches. In BWU, the batches (rows) are left unchanged while the time and process data are 
combined (columns). This combination simply implies that a given process parameter, acquired at two 
different time points, will be considered to represent two different variables (columns). This allows an 
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easy comparison between the different batches[91] or endpoint prediction of quality attributes by 
making use of multivariate analysis. The four BWU unfolded matrices are PBWU [17 × 1000], NBWU [17 
× 20 200], RBWU [17 × 36 600] and FBWU [17 × 8500]. 
 
Figure 4.3. Illustration of batch wise unfolding (BWU) in which each batch represents one row in X and each process 
variable, for each time point, represents a column in X. 
Within each batch, it is also possible to explore the process trajectory and how it relates to the 
changes in the process conditions using a method called OWU (Figure 4.4). In OWU, the process data 
(columns) are left unchanged while the time and batch data are combined (rows). The subsequent 
multivariate analysis provides a straightforward way to monitor batch process trajectories (displaying 
the evolving batch in terms of time)[138]. The four OWU unfolded matrices geometry dimensions are 
POWU [1700 × 10], NOWU [1700 × 202], ROWU [1700 × 366] and FOWU [1700 × 85]. 
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Figure 4.4. Illustration of observation-wise unfolding (OWU) in which each process variable represents one column in X and 
each batch, for each time point, represents a row in X. 
Sub-section 2.7, provides the reader with an overview of the MVDA models used in this work. 
It is however important to specify how the RMSECV was determined. By randomly re-sampling the X 
and Y matrices (bootstrapping) a new set of model parameters can be estimated, allowing to measure 
uncertainty properties, such as confidence limits. In this work, the matrices X and vector y were re-
sampled 50 times selecting a subsample size of 0.7 N, N being the number of batches (17 in this work), 
to estimate RMSECV. The same resampling strategy as to estimate RMSECV was used to estimate the 
distribution of BIP, in order to help estimate the dispersion in the calculated BIPs. 
The computation of the models (PCA, PLS, MBPLS) were all done using in-house Matlab 
R2010b (MathWorks, USA) algorithms (see Annexe III to V). 
4.4 Results and Discussion 
4.4.1 MBPLS on coating thickness 
All temporal variables recorded throughout each batch were included in this analysis as it was 
considered that the process trajectory may have an impact on the endpoint quality attribute. The quality 
of the information provided by temporal and raw materials for in-line quality attributes was evaluated. 
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This task is approached by predicting the endpoint thickness (that has been measured off-line). 
Simultaneously, the usefulness of the data sources (i.e. blocks) used to predict y (critical quality 
attribute) was assessed through the use of the MBPLS’s BIPs.  
The initial MBPLS model was calculated using two latent variables (LV) for ten descriptor 
blocks: NBWU, RBWU, PBWU, M and FBWU in addition to five blocks of random variables for thickness 
(y) prediction. The additional random blocks were used to establish a reference with which the data 
blocks could be compared, random blocks (Z) 1 to 5 were created using Matlab function rand and the 
dimensions were [17 × 70600], [17 × 20200], [17 × 36600], [17 × 8400] and [17 × 100], respectively. 
The global X-variance captured by the calibration model is 22.7% and the model is able to explain 
97.9% of the variance in y, with an R2 of 0.98 and estimated RMSEC of 0.14 µm and RMSECV of 
0.69 µm. However, it is important to stress that this model (given that it contains random variables) 
used solely to assess the quality of the gathered PAT data and rank them in order of importance to 
predict thickness.  
As illustrated by the box plot (Figure 4.5(A)), the Raman data block has the highest BIP, 
followed by process conditions and raw materials, NIR and lastly FBRM and the random variables. 
The information captured by the FBRM is no more useful than a randomly generated variable, given 
that the median BIP value for FBRM is comparable to the random variables, even if FBRM has a wider 
spread. 
It is also useful to analyze the loadings plot (Figure 4.5(B)). LV 1 (global X-variance 11.2% 
and 92% y-variance) clearly separates RBWU from the other sources of information, having two distinct 
groups, one that clusters NBWU, PBWU, M and a second with FBWU and the random variables (Z1 to Z5). 
Reinforcing the idea that Raman is the most useful source of information for endpoint prediction of 
thickness as the other useful sources of information prove to be redundant (NBWU, PBWU, M) or simply 
useless (FBWU and random variables). LV2 (global X-variance 11.5% and 5.9% y-variance) breaks 
apart the groups formed in LV1, separates the FBRM data from the random variables and the process 
data from NBWU and M and further puts RBWU into evidence, showing that the information within the 
groups is somewhat different and could help explain certain differences within some batches. While 
RMSECV results indicated that LV 2 should be included in the model, it only provides a small 
contribution to the y-variance explained by the model (92% for LV 1 vs 5.9% for LV 2). 
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Figure 4.5 (A) BIP box plot of the 3 PAT (NIR, Raman and FBRM), Process data, Raw materials and five random variables 
for thickness prediction. For each box plot, the central rectangle spans from the first quartile to the third quartile, the segment 
inside the rectangle is the median, the “whiskers” above and below are the minimum and the maximum and the dots are the 
outliers. (B)Block-loadings plot for LV1 and 2 for MBPLS thickness model. Legend: NBWU (batch wise unfolded NIR 
matrix), RBWU (batch wise unfolded Raman matrix), PBWU (batch wise unfolded process matrix), M (raw material 
properties matrix), FBWU ( batch wise unfolded FBRM matrix) and  Z1 to 5 (random variable matrices). 
From the discussion above it is possible to conclude that the current set-up of the FBRM is not 
able to provide enough resolution, which is necessary to measure particle growth. FBRM is limited by 
the fact that if the coating is very thin (6.6 µm to 19 µm) compared to the particle diameter (in this 
work either 304.4±6.3 μm with a span of 0.61±0.02 or 314.0±4.7 μm with a span of 0.56±0.01), the 
relative difference between particle size distributions throughout the coating is undetectable given the 
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width of the particle size distributions (given by the span). However, adjusting the position or the 
sampling strategy of the probe may have improved the results, as described by Alshihabi et al.[133] .   
After this initial step, a second calibration model was built using only the useful blocks. When 
calculating a model excluding random variable blocks and FBRM, the four remaining blocks, RBWU, 
PBWU, MBWU and NBWU, are used to compose X. The calibration model is shown in Figure 4.6. In this 
model, the same relative order of importance of the blocks is maintained (Raman > Process> RawMat> 
NIR). The global X-variance captured by the model is only 27.1%, but even so, the two-component 
model is able to explain 93.5% of the y-variance in which R2 of 0.93, an RMSEC of 0.25 µm and 
RMSECV of 0.8 µm.  
 
Figure 4.6 Measured vs predicted end-point thickness using only the significant data blocks (Raman, NIR, Process and Raw 
material data). The labels in the figure correspond to the batch identification number. 
It is important to investigate the source of variance being used to build the MBPLS model.  By 
further analyzing the sub-level loadings, it is possible to determine the main variables within the block 
contributing to the model. In the case of raw materials (data not shown) it is the percentage of anti-
tacking agent in the coating suspension formulation and percentage of Kollicoat® Smartseal 30D, 
while for process data (data not shown), it is the suspension coat weight loss, which is in line with the 
traditional way to determine the endpoint of the process. In the case of Raman and NIR the signal 
intensity decreased throughout the coating process. 
To further investigate spectral responses (both NIR and Raman) of the individual chemical, 
components were compared with spectra of microspheres (before and after coating). As illustrated in 
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Figure 4.7, the absolute intensity of the NIR signal decreases over time. In Figure 4.7 (A) the 
pretreated NIR signal is shown to ease visual interpretation. As the microspheres are coated, the StOH 
signal (main component of the core of the microsphere) is masked by the coating (decreasing signal 
intensity) (Figure 4.7 (B)).  StOH that corresponds to approximately 37, 42 and 46% w/w of total 
microspheres at 23.6, 15.3 and 7% w/w coat weight gain, respectively. The polymeric coating material, 
which is the component that makes up the highest percentage in the coating suspension (12, 8 and 3% 
w/w for 23.6, 15.3 and 7% w/w coat weight gain), has no distinguishable spectral features and the 
remaining components of the coating are at much lower concentrations than the core material and the 
signal is much less intense. 
 
Figure 4.7 (A) NIR spectra at the beginning and at the end of the coating process for batch number 2 (SNV and Savgol 15 
points, 1st order polynomial, 2ndderivative pre-processed). (B) Raw-NIR spectra collected off-line of uncoated microspheres 
(dashed line), coated microspheres (solid line) and stearyl alcohol (dash-dot line), which corresponds to 50%w/w of the 
uncoated microsphere composition. 
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Likewise, in Raman, the spectrum of coated microspheres shows a very similar shape 
resembling the spectra of uncoated microspheres (pretreated signal is shown in Figure 4.8(A)). As the 
microspheres are coated, the core signal is masked by the coating, decreasing the intensity of the signal 
as the thickness of the coating increases (Figure 4.8). As in NIR analysis, the polymeric blend has no 
distinguishable spectral features, and the remaining components of the coating are at much lower 
concentrations than the core material and have a less intense signal. For Raman, the main chemicals 
contributing for the microsphere Raman spectrum are attributed to the StOH and API (crizotinib), 
which is an aminopyridine base, and as such, a conjugated system with a strong Raman signal. 
 
Figure 4.8 (A) Raman spectra at the beginning and at the end of coating run for batch number 2 (SNV pre-processed).(B) 
Raw-Raman spectra collected off-line of uncoated microspheres (dashed line), coated microspheres (solid line), stearyl 
alcohol (red dash-dotted line, 50%w/w of uncoated core composition) and API (blue dash-dotted line, 10%w/w of uncoated 
core composition). Coating spectrum is not presented as it does not have distinguishable peaks. 
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In conclusion, the Raman performance seems to be very satisfactory in that it outperformed the 
other blocks for endpoint prediction of coating thickness based on microscopy reference data. 
4.4.2 MBPLS on dissolution at pH 6.2 
Other coating properties (porosity and roughness[139]) and microsphere core properties 
(particle size, porosity, shape and roughness[139]) are going to determine the dynamic of API release. 
From the patient's perspective, the coating performance is determined by the in vivo taste of the 
microsphere. A simple estimate of in vivo taste masking performance is the use of API dissolution in-
vitro. This justifies why the percentage of API released at pH 6.2 is considered to be a critical quality 
attribute for taste masking[32]. 
The same methodology was applied to the analysis of the dissolution results as for thickness. 
Initially a 2 LVs calibration MBPLS model was estimated using the NBWU, RBWU, FBWU, PBWU, MBWU 
matrices and five random variables (same dimensions as mentioned before) to predict the percentage of 
API released at pH 6.2 at 120 min (y). The global X-variance captured by the model is only 15.9%, the 
model is able to explain 99.8% of the variance in y with an R2 of 1.0, RMSEC 0.04% API released and 
RMSECV of 0.69% API released. As shown in Figure 4.9 (A), Raman is the block that has the highest 
BIP, followed by NIR and process conditions and raw materials. Once again, FBRM information is not 
much better than using random variables. Figure 4.9 (B) shows the loading plot. Where once again, LV 
1 (global X-variance 10.6% and 93.1% y-variance) clearly separates RBWU from the other sources of 
information. LV 2 separates the temporal from the discrete (M and Z) variables and FBWU. Although 
deemed significant when analyzing the RMSECV number of latent variables dependency, LV2 (global 
X-variance 5.3% and 6.7% y-variance) is helping to explain a much lower amount of variance than LV 
1. 
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Figure 4.9 (A) BIP box plot of the 3 PAT (NIR, Raman and FBRM), Process data, Raw materials (RawMat) and five random 
variables for percentage of API released at 120 min in pH 6.2 prediction. (B) Block-loadings plot for LV1 and 2 for MBPLS 
dissolution model. Legend: NBWU (batch wise unfolded NIR matrix), RBWU (batch wise unfolded Raman matrix), PBWU 
(batch wise unfolded process matrix), M (raw material properties matrix), FBWU (batch wise unfolded FBRM matrix) and Z1 
to 5 (random variable matrices). 
This order is again verified when building a calibration model excluding random variables and 
FBRM, this is to say, for the MBPLS model using NBWU, RBWU and PBWU as set of predictor variables 
(X). The global X-variance captured by the model is 23%, and with a two-component model, the 
model is able to explain 98.5% of the variance in y, R2 is 0.99, with RMSEC 0.12% API released and 
RMSECV 0.78% API released. The measured vs. predicted dissolution at 120 min and pH 6.2 for the 
selected model is shown in Figure 4.10. The sources of variation within the blocks were the same as 
previously explained in the previous section. The calculated model is able to predict and distinguish 
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between batches that have high and low percentage of API release. The loading plot once again shows 
that the information on NBWU, PBWU and MBWU blocks is redundant for prediction and putting into 
evidence the importance of the RBWU block. 
 
Figure 4.10 Measured against predicted dissolution values at pH6.2 at 120 min, using significant blocks: Raman, NIR, Process 
and Raw material data. The labels in the figure correspond to the batch identification number. 
MBPLS has proven to be an effective tool to help decide the value of each PAT, being that 
Raman has been identified as being the best suited to monitor both endpoint thickness and dissolution 
performance. A thicker coating compared to a thinner coating with the same microstructure would 
provide a better barrier for dissolution of the API in conditions of the oral cavity and thus a slower API 
release. Intuitively, one would think that an in-line coating thickness measurement would have a great 
performance predicting percentage of API released. However, given the FBRM results, no in-line 
measurement was available and, as such, off-line coating thickness measurements using polarized light 
microscopy (tt) were used as a proxy to facilitate analysis. As illustrated in Figure 4.11, the tt block 
produced the highest BIP value, indicating that an in-line method that can directly measure the 
thickness of the coating (e.g. optical coherence tomography[140], high-speed cameras[141] or even in-
line particle size measurement) would be the preferred method to monitor fluid bed coating when 
predicting the percentage of API released at pH 6.2.  The two latent variable calibration model captures 
a global X-variance of 26.2% and 96.9% of the variance in y. The R2 of the model is 0.97 with an 
RMSEC of 0.17% API released and RMSECV of 0.64% API released. 
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Figure 4.11 BIP of the 3 PAT (NIR, Raman and FBRM), Process data, Raw materials, Off-line measured thickness and five 
random variables for dissolution prediction. Legend: NBWU (batch wise unfolded NIR matrix), RBWU (batch wise unfolded 
Raman matrix), PBWU (batch wise unfolded process matrix), M (raw material properties matrix), FBWU ( batch wise 
unfolded FBRM matrix) tt (off-line measured thickness vector) and  Z1 to 5 (random variable matrices). 
However, it should be noted that, as it has been referenced before in Chapter 3, the coating’s 
performance will not only be dependent on its thickness, but also on the microstructure of the coating 
being applied.  As such, a tool that is able to provide both types of information (i.e. coating thickness 
and properties) would be the preferred tool to gather the most relevant information for monitoring the 
Wurster coating process.   
4.4.3 PLS on Raman 
MBPLS showed that Raman has a superior performance to the other in-line process analytical 
tools. From this point on, the Raman spectra alone (RBWU) will be used in the calibration regression 
models. 
Starting by modelling off-line thickness, the global X-variance captured by the PLS model is 
now 88.1%, and with a two latent variable model, the model explains 71.2% of y-variance. The 
RMSEC is 0.52 µm. It is interesting to see that even though the model has a lower R2 than the 
previously calculated MBPLS for thickness in Figure 4.6 (0.71 vs. 0.93), the RMSECV is practically 
the same (0.67 vs the previous 0.8 µm). This indicates that even though it is harder to predict thickness, 
because there is less data to predict from (smaller X), the MBPLS and the PLS models are equivalent 
in terms of predictive power. We are able to conclude that the calculated model is able to predict within 
a reasonable error (approximately 1 µm) the coating thickness. 
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A second model was built to predict the percentage of API dissolved at 120 min at pH 6.2, the 
global X-variance captured is 78.8%, and with 1 latent variable model, the model is able to explain 
73.8% of the y-variance with a calculated R2 of 0.74, with an RMSEC of 0.5% API released and 
RMSECV is 0.55% API released. When comparing this to the previously calculated MBPLS model in 
Figure 4.10 (RMSECV 0.78% API released), it was possible to achieve a model with equivalent 
predictive power (RMSECV 0.55% API released). It is thus possible to build a reasonable PLS model 
to predict dissolution at pH 6.2 using only Raman data.  
4.4.4 Exploratory data analysis 
PCA is a tool often used for exploratory data analysis[142]. Process understanding and the 
ability of Raman to monitor the process can also be evaluated through BWU and OWU. As explained 
in section 2.6, the former technique will allow the visualization of variations within the batches and the 
latter will be useful to understand that variation by looking at the process trajectories.  
From the score plot shown in Figure 4.12, we can clearly see a differentiation along the first 
principal component between the batches that have low percentage API release (colored in blue) versus 
the ones that have a high API release (colored in red). In this case, 78.8% of the variance between the 
Raman spectra corresponds to the variation in dissolution performance at pH 6.2 at 120 min, which 
explains the high quality of the correlation model for dissolution. 
 
Figure 4.12 Score plot of the first two principal components of PCA for BWU Raman data. Color code: % API released after 
120 min in dissolution medium at pH 6.2. The labels in the figure correspond to the batch identification number. 
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Comparing the score plot in Figure 4.13 (OWU – colored by standardized batch time) with the 
information provided in the score plot in Figure 4.12 (BWU – colored by percentage of API released at 
120 min at pH 6.2), we see that batches with a high API release, such as batches 1, 3 and 16, have 
lower endpoint values in PC1 of Figure 4.13. Batches that have a lower percentage of API release, for 
example batches 4, 5 and 11, correspond to long runs (variation along PC1 of Figure 4.13). The authors 
would like to reinforce the idea that here the time is a standardize time and that not all (short or long) 
batches took the same time. This implies that a longer coating process leads to more coating being 
deposited and thus thicker coating and a lower percentage of API release after 120 min of dissolution 
testing.  
The starting offset along component two remains unclear. However, the effect of spray rate in 
the acquired Raman signal is observable in inflections of the second principal component. When 
comparing the batch records to the trajectories’ inflection points (present in PC2) of the different 
batches, they correspond to changes in spray rate. For example, batch 7, for which the spray rate was 
set to 5 g/min, had a sudden decrease in spray rate at 55% completion (1st inflection point) from 5 
g/min to 0 g/min (due to a blockage in the spray line): the spray rate then went back to 5 g/min at 81%, 
which corresponds with the second inflection point in the image. Reader is advised to consult online 
version of this document for clarity. This demonstrates the ability of Raman (in-line PAT) to 
adequately monitor process performance and spot out-of-trend events. 
 
Figure 4.13 Score plot of the first two principal components of PCA for OWU Raman data. Color code: relative process time 
of each batch (0 to 100%). The labels in the figure correspond to the batch identification number. 
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4.5 Conclusion 
In this work we investigated the potential benefits of using near-infrared (NIR), Raman, 
focused beam reflectance measurement (FBRM), process data and raw material properties to predicting 
API dissolution in simulated saliva being used as a surrogate for taste masking performance of reverse 
enteric polymer applied to melt-spray-congeal microspheres. Multiblock partial least squares (MBPLS) 
can provide a simple way to interpret one-to-one comparisons of different sources of information (or 
even combine them).  It was possible to establish a lower threshold for the block importance for 
prediction that helped identify Raman as the tool best able to predict the taste masking performance 
and clearly illustrate that FBRM was not suitable for the task with the current setup and sampling 
strategy tested. 
Strikingly, the partial least squares Raman model built proved to be as good as the MBPLS 
combining the useful blocks of information (NIR, Raman, Process and Raw Material). Raman can be 
used to monitor not only the endpoint coating thickness, but more importantly (for the intended 
application) the percentage of active pharmaceutical ingredients release at neutral pH.  
Through observation-wise unfolding and batch-wise unfolding, it was possible to show that the 
variation in Raman correlates to the variations in product performance, showing that Raman can be 
used to monitor the coating process (beginning to end) and to identify process disruptions (such as 
spray rate changes).  This work contributes to demonstrating the usefulness of MBPLS and how 
Raman could potentially be used in the future to establish a control strategy for fluid bed coating. 
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CHAPTER 5 CONCLUSION 
5.1 Conclusion en français 
Le masquage du goût est devenu un élément important du développement de formes 
médicamenteuses dans l’industrie pharmaceutique. Un procédé de fabrication plateforme qui 
permettrait de développer rapidement de nouvelles formulations pour la population pédiatrique devra 
reposer sur une approche efficace afin de masquer l’amertume des principes actifs (PA). 
Du point de vue du QbD, la connaissance des produits et la compréhension des procédés sont 
essentielles pour la conception d’un procédé de fabrication pharmaceutique. En utilisant les outils du 
QbD, il a été possible d’évaluer la criticité des paramètres du procédé et de la formulation de la 
solution d’enrobage avec Kollicoat®Smartseal 30D, et de comprendre le rôle crucial de la 
microstructure du film d’enrobage pour le développement de microsphères dont le goût est masqué 
(chapitre 3). 
Sept variables clefs du procédé d’enrobage avec Wurster ont été sélectionnées puis évaluées 
par un plan d’expérience D-optimal et une analyse de la variance. Le pourcentage de PA libéré à pH 
6,2 a été utilisé comme méthode de substitution pour déterminer la performance au chapitre du 
masquage de goût du Kollicoat® Smartseal. Les sept variables étudiées été : la température du lit de 
produit, le débit d’air entrant, la pression d’air atomisé, le débit du spray (paramètres du procédé), le 
taux d’enrobage, le niveau de plastifiant, la présence de solides dans la suspension d’enrobage 
(caractéristique du matériel) et le durcissement. Les résultats montrent que le niveau d’enrobage et le 
niveau de plastifiant sont les paramètres critiques du procédé et renforcent l’importance du 
durcissement pour réduire la variabilité entre les lots en favorisant la formation d’un film complet. Le 
lien entre les caractéristiques du matériau, les paramètres du procédé et les attributs de qualité a permis 
une meilleure compréhension des paramètres qui affectent le profil de libération du PA à pH buccal 
(in-vitro). Il a été démontré que tant l’épaisseur que la morphologie de l’enrobage ont un impact sur la 
dissolution dans une salive simulée. 
Les travaux futurs dans ce domaine devraient inclure une caractérisation quantitative de la 
porosité des films appliqués, ainsi qu’une évaluation de l’influence des principales variables de 
formulation et de procédé sur la porosité pour obtenir un meilleur contrôle de la performance de la 
dissolution à pH 6,2. De plus, une meilleure compréhension du mécanisme phénoménologique de la  
libération demeure nécessaire. 
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L’operation d’enrobage en lit fluidisé est un processus complexe de transfert de chaleur et de 
masse qui implique différents microprocessus, tels que la formation de gouttelettes, l'évaporation, le 
transfert de chaleur, l'impact des gouttelettes et le comportement des particules. Dans les travaux 
futurs, il serait important de comprendre les mécanismes fondamentaux à la fois du processus 
d’enrobage et de l'étape de durcissement afin de faciliter le choix de l'épaisseur du revêtement, la 
conception d'une stratégie de contrôle, la mise à l'échelle du processus et aussi pour faciliter le transfert 
du processus d’enrobage pour de microsphères avec d’autres PAs. 
L’utilisation d’outils d’analyse des procédés et d’une stratégie d’analyse avancée des données a 
été essentielle pour : i) fournir un moyen simple de comparer les informations provenant de différentes 
sources (et comment les combiner), ii) améliorer les connaissances sur les paramètres du procédé qui 
influencent l’enrobage pour des films fins (chapitre 4).  
Étonnamment, ces travaux ont montré que Raman est un outil utile pour suivre le procédé 
d’enrobage aussi performant que le MBPLS combinant les blocs d’information utiles (NIR, Raman, 
procédure et matière première), car  Raman s’est révélé efficace pour suivre les trajectoires du procédé 
et analyser les attributs de qualité critiques définis (épaisseur et dissolution à pH 6,2). Du point de vue 
du QbD, la prochaine étape consistera à élaborer une stratégie de contrôle en utilisant les connaissances 
recueillies sur le procédé pour contrôler les paramètres critiques du procédé en vue d’obtenir des 
attributs de qualité critiques constants. Néanmoins, comme le montrent les résultats du chapitre 3, un 
outil capable de fournir des informations sur l’épaisseur du film et sur la structure des microsphères 
serait l’outil idéal pour recueillir des informations encore plus pertinentes pour le suivi du procédé 
d’enrobage avec un Wurster. 
Afin de garantir le succès d’une plateforme utilisant des microsphères enrobées avec 
Kollicoat®Smartseal 30D, il faut d’assurer que le film de polymère est capable d’adhérer à la surface 
de la microsphère. Les deux grandes forces qui influencent l’adhésion sont : i) la tension interfaciale, 
qui dépend de la formulation de la microsphère, et ii) les contraintes internes du film. L’étude de la 
distribution du PA dans la microsphère sera la clef du succès de cette plateforme. Un second élément 
est la solubilité du PA lui-même, qui peut aussi avoir une incidence sur son taux de libération. Une 
étude où le système de classification biopharmaceutique (système qui classe les PA selon leur 
perméabilité et leur solubilité) est pris en considération, doit être réalisée pour s’assurer du succès de 
cette plateforme pédiatrique.  
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De manière générale, cette recherche a pour but de faciliter le développement de nouveaux 
produits pédiatriques conçus pour surmonter l’une des principales limites des médicaments 
pédiatriques actuels faible appétibilité). Bien que ce projet porte essentiellement sur les besoins 
pédiatriques, les résultats peuvent être appliqués à des patients gériatriques, car les microsphères 
peuvent être utilisées comme forme médicamenteuse pour les groupes de patients qui ont de la 
difficulté à avaler certaines formes pharmaceutiques telles que les comprimés ou les gélules. 
5.2 Conclusion in English 
Taste masking has become an important part of the dosage form development in the 
pharmaceutical industry because of increasing reports of noncompliance. A platform solution that 
would enable the rapid development of new formulations to pediatrics will need to have an effective 
approach to the bitter API taste problem. 
From a QbD perspective product knowledge and process understanding are essential to design 
the pharmaceutical manufacturing process. Using QbD tools, it was possible to assess the criticality of 
both processing parameters and coating formulation of the Kollicoat®Smartseal 30D coating process 
and understand the crucial role of coating microstructure for the development of taste masked 
microspheres (Chapter 3). 
A screening of seven key variables in a Wurster coating process was evaluated by D-optimal 
design and by analysis of variance. The percentage of API released at pH 6.2 was used as a surrogate 
method for taste masking performance evaluation of Kollicoat® Smartseal. The seven studied variables 
were: product bed temperature, inlet airflow, atomizing air pressure, spray rate (process parameters), 
coating level, plasticizer level, solids in coating suspension (material attributes) and curing. Results 
show that coating levels and plasticizer levels are the critical process parameters and reinforce the 
importance of curing to reduce the overall variability within the batch by promoting complete film 
formation. The links between material attributes, process parameters and quality attributes were 
demonstrated to allow a better understanding of the parameters that affect the API release profile at 
mouth pH (in vitro). It was demonstrated that not only thickness, but also coating morphology have an 
impact on the dissolution in 50 mM potassium phosphate buffer at pH 6.2. 
Future work in this area should include quantitative characterization of the porosity of the 
coatings being applied, as well as the influence of key formulation and process variables on the 
porosity to gain a better control of the dissolution performance at pH 6.2. Further understanding of the 
phenomenological curing and release mechanism of Kollicoat®Smartseal 30D coating is still needed. 
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Fluid bed coating is a complex heat and mass transfer process that involves different 
microprocesses, such as droplet formation, evaporation, heat transfer, droplet impingement and particle 
behaviours. In future work, it would be important to understand the fundamental mechanisms behind 
both the coating process and the curing step in order to facilitate the choice of coating thickness, design 
of a control strategy, scale-up of the process and as well facilitate the transfer of coating process to 
micropsheres made with other APIs. 
The use of PAT and advance data analysis strategy was key to (i) provide a simplistic way to 
compare different sources of information (and how to combine them) (ii) improve knowledge about 
process parameter influencing coating for thin coatings (Chapter 4). 
Surprisingly, this work has shown that Raman is as efficient as combining the useful blocks of 
information (NIR, Raman, Process and Raw Material) by MBPLS to monitor the coating process.  
Raman spectroscopy has proven to be an efficient tool to monitor process trajectories and analyze the 
defined CQAs (thickness and dissolution at pH 6.2). From a QbD perspective the next step would be to 
develop a control strategy using the gathered process understanding to control CPPs so as to achieve 
consistent CQAs. Nevertheless, as per results shown in Chapter 3, a tool that is able to provide 
information regarding coating thickness and coating microstructure would be the prefered tool to 
gather even more relevant information for monitoring the Wurster coating process. 
In order to guarantee the success of the platform approach using MSC microspheres coated 
with Kollicoat®Smartseal 30D one needs to ensure that the polymeric film is able to adhere to the 
MSC core surface. Two major forces that influence adhesion are: (i) the strength of the interfacial 
bonds, which are dependent on the core formulation, and (ii) the internal stresses within the film. 
Studying the API distribution within the MSC core will be key to the success of this platform. A 
second element to keep in mind is that the solubility of the API itself will also impact the release rate 
from the API. Conducting a study where the biopharmaceutics classification system (system that 
classifies APIs based on their permeability and solubility) is taken into account needs to be conducted 
to guarantee the success of this pediatric platform. 
Overall, this research aims at facilitating the development of new pediatric products designed 
to overcome one of the major limitations with current pediatric medications (poor palatability). 
Although this project focuses on pediatric needs, results can also be transferred to geriatric patients as 
microspheres can be used as a platform approach for patient groups that have challenges with 
swallowing more typical tablet and capsule drug products. 
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ANNEXE I 
Table I. 1 Coating conditions for each batch. 
Batch 
number 
Product Bed 
Temperature 
(°C) 
Inlet 
Airflow 
(m3/h) 
Atomizing 
Air 
Pressure 
(bar) 
Spray 
Rate 
(g/min) 
Coating 
Level 
(% w/w) 
Plasticizer 
Level 
(% w/w dry 
polymer) 
Solids in 
suspension 
(% w/w) 
1 25.0 60 3 11 7.00 20 15.68 
2 28.5 50 2 8 15.3 16 19.60 
3 25.0 40 1 5 7.00 12 15.68 
4 32.0 40 1 5 23.6 12 23.52 
5 32.0 40 1 11 23.6 20 15.68 
6 28.5 50 2 8 15.3 16 19.60 
7 25.0 60 3 5 7.00 12 23.52 
8 32.0 60 1 5 7.00 20 23.52 
9 25.0 40 3 5 23.6 20 23.52 
10 32.0 60 1 11 7.00 12 15.68 
11 32.0 60 3 11 23.6 20 23.52 
12 32.0 40 3 11 7.00 12 23.52 
13 32.0 40 3 5 7.00 20 15.68 
14 25.0 40 1 11 7.00 20 23.52 
15 32.0 60 3 5 23.6 12 15.68 
16 25.0 60 1 11 23.6 12 23.52 
17 25.0 60 1 5 23.6 20 15.68 
18 25.0 40 3 11 23.6 12 15.68 
19 28.5 50 2 8 15.3 16 19.60 
20 32.0 60 1 11 7.00 12 15.68 
21 25.0 60 1 11 23.6 12 15.68 
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ANNEXE II 
Table II. 1 ANOVA for main factor model for percentage of API release after 30 min of uncured coated microspheres 
Source Sum of Squares 
Degrees of 
Freedom 
Mean 
Square 
F value p-value 
Block 1705.0 2 852.5   
Main factors      
Product Bed Temperature 140.9 1 140.9 1.5 0.2265 
Inlet Airflow 6.9 1 6.9 0.1 0.7872 
Atomizing Air Pressure 942.0 1 942.0 10.0 0.0026 
Spray Rate 302.2 1 302.2 3.2 0.0789 
Coating Level 18632.3 1 18632.3 197.9 
< 
0.0001 
Plasticizer Level 8708.0 1 8708.0 92.5 
< 
0.0001 
Solids in Suspension 27.9 1 27.9 0.3 0.5883 
Residual 4989.4 53 94.1   
Total (corrected) 36423.8 62    
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Table II. 2 ANOVA for main factor model for percentage of API release after 60 min of uncured coated microspheres 
Source Sum of Squares 
Degrees of 
Freedom 
Mean 
Square 
F value p-value 
Block 1479.8 2 739.9   
Main factors      
Product Bed Temperature 225.7 1 225.7 3.0 0.0900 
Inlet Airflow 53.6 1 53.6 0.7 0.4037 
Atomizing Air Pressure 1038.2 1 1038.2 13.7 0.0005 
Spray Rate 2.4 1 2.4 0.0 0.8591 
Coating Level 13292.5 1 13292.5 175.7 
< 
0.0001 
Plasticizer Level 4742.6 1 4742.6 62.7 
< 
0.0001 
Solids in Suspension 2.2 1 2.2 0.0 0.8654 
Residual 4009.2 53 75.6   
Total (corrected) 25033.6 62    
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Table II. 3 ANOVA for main factor model for percentage of API release after 90 min of uncured coated microspheres 
Source Sum of Squares 
Degrees of 
Freedom 
Mean 
Square 
F value p-value 
Block 1379.0 2 689.5   
Main factors      
Product Bed Temperature 176.8 1 176.8 2.4 0.1288 
Inlet Airflow 39.0 1 39.0 0.5 0.4721 
Atomizing Air Pressure 999.7 1 999.7 13.5 0.0006 
Spray Rate 124.7 1 124.7 1.7 0.2007 
Coating Level 10228.6 1 10228.6 137.7 
< 
0.0001 
Plasticizer Level 2945.9 1 2945.9 39.6 
< 
0.0001 
Solids in Suspension 8.4 1 8.4 0.1 0.7386 
Residual 3937.7 53 74.3   
Total (corrected) 19842.1 62    
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Table II. 4 ANOVA for main factor model for percentage of API release after 120 min of uncured coated microspheres 
Source Sum of Squares 
Degrees of 
Freedom 
Mean 
Square 
F value p-value 
Block 1204.1 2 602.0   
Main factors      
Product Bed Temperature 196.5 1 196.5 3.2 0.0802 
Inlet Airflow 10.3 1 10.3 0.2 0.6845 
Atomizing Air Pressure 867.9 1 867.9 14.1 0.0004 
Spray Rate 229.2 1 229.2 3.7 0.0594 
Coating Level 7659.2 1 7659.2 124.0 
< 
0.0001 
Plasticizer Level 1902.2 1 1902.2 30.8 
< 
0.0001 
Solids in Suspension 3.9 1 3.9 0.1 0.8031 
Residual 3273.4 53 61.8   
Total (corrected) 15317.2 62    
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Table II. 5 ANOVA for main factor model for percentage of API release after 30 min of cured coated microspheres 
Source Sum of Squares 
Degrees of 
Freedom 
Mean 
Square 
F value p-value 
Block 3558.8 2 1779.4   
Main factors      
Product Bed Temperature 560.0 1 560.0 2.5 0.1196 
Inlet Airflow 121.2 1 121.2 0.5 0.4650 
Atomizing Air Pressure 28.4 1 28.4 0.1 0.7230 
Spray Rate 1186.4 1 1186.4 5.3 0.0253 
Coating Level 31279.0 1 31279.0 139.8 
< 
0.0001 
Plasticizer Level 5255.7 1 5255.7 23.5 
< 
0.0001 
Solids in Suspension 95.0 1 95.0 0.4 0.5176 
Residual 11860.7 53 223.8   
Total (corrected) 56877.1 62    
 
  
94 ANNEXE II  
 
Table II. 6 ANOVA for main factor model for percentage of API release after 60 min of cured coated microspheres 
Source Sum of Squares 
Degrees of 
Freedom 
Mean 
Square 
F value p-value 
Block 4372.2 2 2186.1   
Main factors      
Product Bed Temperature 686.9 1 686.9 3.0 0.0892 
Inlet Airflow 102.6 1 102.6 0.4 0.5062 
Atomizing Air Pressure 92.1 1 92.1 0.4 0.5289 
Spray Rate 1706.0 1 1706.0 7.4 0.0086 
Coating Level 48906.7 1 48906.7 213.5 
< 
0.0001 
Plasticizer Level 6198.3 1 6198.3 27.1 
< 
0.0001 
Solids in Suspension 4.1 1 4.1 0.0 0.8939 
Residual 12141.5 53 229.1   
Total (corrected) 78333.4 62    
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Table II. 7 ANOVA for main factor model for percentage of API release after 90 min of cured coated microspheres 
Source Sum of Squares 
Degrees of 
Freedom 
Mean 
Square 
F value p-value 
Block 3487.1 2 1743.6   
Main factors      
Product Bed Temperature 963.1 1 963.1 5.0 0.0291 
Inlet Airflow 112.5 1 112.5 0.6 0.4468 
Atomizing Air Pressure 147.7 1 147.7 0.8 0.3837 
Spray Rate 2151.4 1 2151.4 11.2 0.0015 
Coating Level 55282.3 1 55282.3 288.7 
< 
0.0001 
Plasticizer Level 6332.3 1 6332.3 33.1 
< 
0.0001 
Solids in Suspension 47.8 1 47.8 0.2 0.6193 
Residual 10147.4 53 191.5   
Total (corrected) 83293.0 62    
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Table II. 8 ANOVA for main factor model for percentage of API release after 120 min of cured coated microspheres 
Source Sum of Squares 
Degrees of 
Freedom 
Mean 
Square 
F value p-value 
Block 2711.7 2 1355.9   
Main factors      
Product Bed Temperature 928.8 1 928.8 6.4 0.0144 
Inlet Airflow 103.4 1 103.4 0.7 0.4025 
Atomizing Air Pressure 253.1 1 253.1 1.7 0.1924 
Spray Rate 2096.6 1 2096.6 14.4 0.0004 
Coating Level 59187.9 1 59187.9 407.7 
< 
0.0001 
Plasticizer Level 5566.4 1 5566.4 38.3 
< 
0.0001 
Solids in Suspension 120.7 1 120.7 0.8 0.3660 
Residual 7694.7 53 145.2   
Total (corrected) 83214.4 62    
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ANNEXE III 
Principal Component Analysis (PCA) 
function [T P Varex Eigenvalues] = fct_PCA(X,nbPC) 
% PCA 
X0 = X; 
P = []; 
T = []; 
SSX = []; 
error = realmax; 
  
for i = 1:nbPC 
    t_temp = ones(size(X,1),1); 
    t = ones(size(X,1),1); 
     
    while error > 1E-10 
     
        p = X'*t / (t'*t); 
        p = p / norm(p); 
        t = X*p / (p'*p); 
         
        % Check t convergence -------------------- 
        error = sum((t-t_temp).^2); 
        t_temp = t; 
        % ---------------------------------------- 
    end 
     
    X = X - t*p'; 
    P = [P p]; 
    T = [T t]; 
        % Sum of squares ----------- 
    Xhat = t*p'; 
    ssX0 = sum(sum(X0 .* X0)); 
    ssX = sum(sum(Xhat .* Xhat)); 
    ssX = ssX / ssX0; 
    SSX = [SSX; ssX]; 
    % -------------------------- 
    error = realmax; 
         
end 
  
% Varience explained by the model 
Varex = SSX; 
% Eigenvalues 
Eigenvalues = var(T); 
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ANNEXE IV 
Partial Least Squares (PLS) 
function [T P W C U B SSX SSY] = fct_PLS(X,Y,nbPC) 
  
E = X; % At iteration 0, there are no components and X = E 
F = Y; % At iteration 0, there are no components and Y = F 
% Create empty variables 
T = [];  
P = [];  
W = []; 
C = []; 
U = []; 
B = []; 
 
u = randn(size(Y,1),1); % Create u seed variable 
 
% In order to check convergence, we need dummy u and t variables 
t_temp = ones(size(X,1),1);  
u_temp = ones(size(X,1),1);  
error_t = realmax; 
error_u = realmax; 
  
% Select number of components 
size1 = size(X,1); 
size2 = size(X,2); 
  
% Sum of square variables for :  
SSX = []; 
SSY = []; 
  
for i = 1:nbPC; 
  
    while (error_t > 1E-20) && (error_u > 1E-20) 
  
    w = (u'*E / (u'*u)); 
    w = w'; 
    w = w/norm(w); 
    t = E*w / (w'*w); 
    c = F'*t / (t'*t); 
    c = c/norm(c); 
    u = F*c / (c'*c); 
     % Check t and u convergence -------------- 
    error_t = sum((t-t_temp).^2); 
    t_temp = t; 
    error_u = sum((u-u_temp).^2); 
    u_temp = u; 
    % ---------------------------------------- 
    end 
  
p = E'*t / (t'*t); 
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% Scaling used by PLS Toolbox 
% This makes it possible to have: nomr(W)=1 
t = t*norm(p); 
p = p/norm(p); 
  
b = u'*t /(t'*t); 
  
T(:,i) = t; 
P(:,i) = p; 
W(:,i) = w; 
C(:,i) = c; 
U(:,i) = u; 
B(i,i) = b; 
  
  
% Sum of squares ----------- 
Xhat = t*p'; 
ssX0 = sum(sum(X .* X)); 
ssX = sum(sum(Xhat .* Xhat)); 
ssX = ssX / ssX0; 
SSX = [SSX; ssX]; 
  
Yhat = b*t*c'; 
ssY0 = sum(sum(Y .* Y)); 
ssY = sum(sum(Yhat .* Yhat)); 
ssY = ssY / ssY0; 
SSY = [SSY; ssY]; 
% -------------------------- 
  
% Deflate variables 
E = E - t*p'; 
F = F - b*t*c'; 
  
error_t = realmax; 
error_u = realmax; 
  
end 
  
disp('Percent Variance Captured by Model X-Block') 
Varex_X = sum(SSX); 
  
%disp('Percent Variance Captured by Model Y-Block') 
Varex_Y = sum(SSY); 
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ANNEXE V 
Multiblock Partial Least Squares (MBPLS) (for one y block only) 
function [Tscores Wloads Pt SS B Q] = fct_mbPLS_X_mod(nbPC, Y, Xa, Xb, Xc, 
Xd, Xe, Xf, Xg, Xh, Xi, Xj, Xk, Xl) 
  
% fct_mbPLS_X 
  
% Check number of input arguments 
% As nbPC and Y are mandatory, number of blocks is: 
nb_blocks = nargin - 2; 
  
  
% Create empty variables if nb_blocks is less than 12 
  
if nb_blocks < 12  
    Xl = []; 
end 
if nb_blocks < 11  
    Xk = []; 
end 
if nb_blocks < 10  
    Xj = []; 
end 
if nb_blocks < 9  
    Xi = []; 
end 
if nb_blocks < 8  
    Xh = []; 
end 
if nb_blocks < 7  
    Xg = []; 
end 
if nb_blocks < 6  
    Xf = []; 
end 
if nb_blocks < 5  
    Xe = []; 
end 
if nb_blocks < 4  
    Xd = []; 
end 
if nb_blocks < 3  
    Xc = []; 
end 
if nb_blocks < 2  
    Xb = []; 
end 
  
% Save copy of the original variables 
Y0 = Y; 
Xa0 = Xa; 
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Xb0 = Xb; 
Xc0 = Xc; 
Xd0 = Xd; 
Xe0 = Xe; 
Xf0 = Xf; 
Xg0 = Xg; 
Xh0 = Xh; 
Xi0 = Xi; 
Xj0 = Xj; 
Xk0 = Xk; 
Xl0 = Xl; 
  
X = [Xa Xb Xc Xd Xe Xf Xg Xh Xi Xj Xk Xl]; 
X0 = X; 
X2=X; 
  
Pa = []; 
Pb = []; 
Pc = []; 
Pd = []; 
Pe = []; 
Pf = []; 
Pg = []; 
Ph = []; 
Pi = []; 
Pj = []; 
Pk = []; 
Pl = []; 
  
Pt=[]; 
Tt = []; 
  
Ta = []; 
Tb = []; 
Tc = []; 
Td = []; 
Te = []; 
Tf = []; 
Tg = []; 
Th = []; 
Ti = []; 
Tj = []; 
Tk = []; 
Tl = []; 
  
ta = []; 
tb = []; 
tc = []; 
td = []; 
te = []; 
tf = []; 
tg = []; 
th = []; 
ti = []; 
tj = []; 
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tk = []; 
tl = []; 
  
U = []; 
W = []; 
Q = []; 
  
Wa = []; 
Wb = []; 
Wc = []; 
Wd = []; 
We = []; 
Wf = []; 
Wg = []; 
Wh = []; 
Wi = []; 
Wj = []; 
Wk = []; 
Wl = []; 
  
wa = []; 
wb = []; 
wc = []; 
wd = []; 
we = []; 
wf = []; 
wg = []; 
wh = []; 
wi = []; 
wj = []; 
wk= []; 
wl= []; 
  
SSXa = []; 
SSXb = []; 
SSXc = []; 
SSXd = []; 
SSXe = []; 
SSXf = []; 
SSXg = []; 
SSXh = []; 
SSXi = []; 
SSXj = []; 
SSXk= []; 
SSXl= []; 
  
ssXa = 0; 
ssXb = 0; 
ssXc = 0; 
ssXd = 0; 
ssXe = 0; 
ssXf = 0; 
ssXg = 0; 
ssXh = 0; 
ssXi = 0; 
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ssXj = 0; 
ssXk=0; 
ssXl=0; 
  
SSX = []; 
SSY = []; 
  
error_t = realmax; 
error_u = realmax; 
  
for i = 1:nbPC 
    tt_temp = ones(size(Xa,1),1); 
    u_temp = ones(size(Xa,1),1); 
    u = ones(size(Xa,1),1); 
     
    while (error_t > 1E-20) && (error_u > 1E-20) 
     
        if nb_blocks >= 1  
            wa = Xa'*u / (u'*u); 
            wa = wa / norm(wa); 
            ta = Xa*wa;  
        end 
        if nb_blocks >= 2  
            wb = Xb'*u / (u'*u); 
            wb = wb / norm(wb); 
            tb = Xb*wb;  
        end 
        if nb_blocks >= 3  
            wc = Xc'*u / (u'*u); 
            wc = wc / norm(wc); 
            tc = Xc*wc;  
        end 
        if nb_blocks >= 4  
            wd = Xd'*u / (u'*u); 
            wd = wd / norm(wd); 
            td = Xd*wd;  
        end 
        if nb_blocks >= 5  
            we = Xe'*u / (u'*u); 
            we = we / norm(we); 
            te = Xe*we;  
        end 
        if nb_blocks >= 6  
            wf = Xf'*u / (u'*u); 
            wf = wf / norm(wf); 
            tf = Xf*wf;  
        end 
        if nb_blocks >= 7  
            wg = Xg'*u / (u'*u); 
            wg = wg / norm(wg); 
            tg = Xg*wg;  
        end 
  
        if nb_blocks >= 8  
            wh = Xh'*u / (u'*u); 
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            wh = wh / norm(wh); 
            th = Xh*wh;  
        end 
   
        if nb_blocks >= 9 
            wi = Xi'*u / (u'*u); 
            wi = wi / norm(wi); 
            ti = Xi*wi;  
        end 
  
        if nb_blocks >= 10 
            wj = Xj'*u / (u'*u); 
            wj = wj / norm(wj); 
            tj = Xj*wj;  
        end 
         
        if nb_blocks >= 11 
            wk = Xk'*u / (u'*u); 
            wk = wk / norm(wk); 
            tk = Xk*wk;  
        end 
         
        if nb_blocks >= 12 
            wl = Xl'*u / (u'*u); 
            wl = wl / norm(wl); 
            tl = Xl*wl;  
        end 
  
        T = [ta tb tc td te tf tg th ti tj tk tl]; 
         
        wt = T'*u / (u'*u); 
        wt = wt / norm(wt); 
  
        tt = T*wt / (wt'*wt); 
  
        q = Y'*tt / (tt'*tt); 
        u = Y*q / (q'*q); 
         
    % Check t and u convergence -------------- 
    error_tt = sum((tt-tt_temp).^2); 
    tt_temp = tt; 
    error_u = sum((u-u_temp).^2); 
    u_temp = u; 
    % ---------------------------------------- 
         
    end 
     
        if nb_blocks >= 1  
            pat = Xa'*tt / (tt'*tt); 
            Xa = Xa - tt *pat'; 
        end 
        if nb_blocks >= 2  
            pbt = Xb'*tt / (tt'*tt); 
            Xb = Xb - tt *pbt'; 
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        end 
        if nb_blocks >= 3 
            pct = Xc'*tt / (tt'*tt); 
            Xc = Xc - tt *pct'; 
        end 
        if nb_blocks >= 4 
            pdt = Xd'*tt / (tt'*tt); 
            Xd = Xd - tt *pdt'; 
        end 
        if nb_blocks >= 5 
            pet = Xe'*tt / (tt'*tt); 
            Xe = Xe - tt *pet'; 
        end 
        if nb_blocks >= 6 
            pft = Xf'*tt / (tt'*tt); 
            Xf = Xf - tt *pft'; 
        end 
        if nb_blocks >= 7 
            pgt = Xg'*tt / (tt'*tt); 
            Xg = Xg - tt *pgt'; 
        end 
        if nb_blocks >= 8 
            pht = Xh'*tt / (tt'*tt); 
            Xh = Xh - tt *pht'; 
        end 
        if nb_blocks >= 9 
            pit = Xi'*tt / (tt'*tt); 
            Xi = Xi - tt *pit'; 
        end 
        if nb_blocks >= 10 
            pjt = Xj'*tt / (tt'*tt); 
            Xj = Xj - tt *pjt'; 
        end 
        if nb_blocks >= 11 
            pkt = Xk'*tt / (tt'*tt); 
            Xk = Xk - tt *pkt'; 
        end         
        if nb_blocks >= 12 
            plt = Xl'*tt / (tt'*tt); 
            Xl = Xl - tt *plt'; 
        end   
         
         
         
X2=[Xa Xb Xc Xd Xe Xf Xg Xh Xi Xj Xk Xl]; 
  
    % Sum of squares ----------- 
if nb_blocks >= 1 
    Xahat = tt*pat'; 
    ssXa0 = sum(sum(Xa0 .* Xa0)); 
    ssXa = sum(sum(Xahat .* Xahat)); 
    ssXa = ssXa / ssXa0; 
    SSXa = [SSXa; ssXa]; 
end 
if nb_blocks >= 2 
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    Xbhat = tt*pbt'; 
    ssXb0 = sum(sum(Xb0 .* Xb0)); 
    ssXb = sum(sum(Xbhat .* Xbhat)); 
    ssXb = ssXb / ssXb0; 
    SSXb = [SSXb; ssXb]; 
end 
if nb_blocks >= 3 
    Xchat = tt*pct'; 
    ssXc0 = sum(sum(Xc0 .* Xc0)); 
    ssXc = sum(sum(Xchat .* Xchat)); 
    ssXc = ssXc / ssXc0; 
    SSXc = [SSXc; ssXc];     
end 
if nb_blocks >= 4 
    Xdhat = tt*pdt'; 
    ssXd0 = sum(sum(Xd0 .* Xd0)); 
    ssXd = sum(sum(Xdhat .* Xdhat)); 
    ssXd = ssXd / ssXd0; 
    SSXd = [SSXd; ssXd];     
end 
if nb_blocks >= 5 
    Xehat = tt*pet'; 
    ssXe0 = sum(sum(Xe0 .* Xe0)); 
    ssXe = sum(sum(Xehat .* Xehat)); 
    ssXe = ssXe / ssXe0; 
    SSXe = [SSXe; ssXe]; 
end 
if nb_blocks >= 6 
    Xfhat = tt*pft'; 
    ssXf0 = sum(sum(Xf0 .* Xf0)); 
    ssXf = sum(sum(Xfhat .* Xfhat)); 
    ssXf = ssXf / ssXf0; 
    SSXf = [SSXf; ssXf];     
end 
if nb_blocks >= 7 
    Xghat = tt*pgt'; 
    ssXg0 = sum(sum(Xg0 .* Xg0)); 
    ssXg = sum(sum(Xghat .* Xghat)); 
    ssXg = ssXg / ssXg0; 
    SSXg = [SSXg; ssXg];    
end 
if nb_blocks >= 8 
    Xhhat = tt*pht'; 
    ssXh0 = sum(sum(Xh0 .* Xh0)); 
    ssXh = sum(sum(Xhhat .* Xhhat)); 
    ssXh = ssXh/ ssXh0; 
    SSXh = [SSXh; ssXh];    
end 
if nb_blocks >= 9 
    Xihat = tt*pit'; 
    ssXi0 = sum(sum(Xi0 .* Xi0)); 
    ssXi = sum(sum(Xihat .* Xihat)); 
    ssXi = ssXi / ssXi0; 
    SSXi = [SSXi; ssXi];    
end 
if nb_blocks >= 10 
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    Xjhat = tt*pjt'; 
    ssXj0 = sum(sum(Xj0 .* Xj0)); 
    ssXj = sum(sum(Xjhat .* Xjhat)); 
    ssXj = ssXj / ssXj0; 
    SSXj = [SSXj; ssXj];    
end 
  
if nb_blocks >= 11 
    Xkhat = tt*pkt'; 
    ssXk0 = sum(sum(Xk0 .* Xk0)); 
    ssXk = sum(sum(Xkhat .* Xkhat)); 
    ssXk = ssXk / ssXk0; 
    SSXk = [SSXk; ssXk];    
end 
   
if nb_blocks >= 12 
    Xlhat = tt*plt'; 
    ssXl0 = sum(sum(Xl0 .* Xl0)); 
    ssXl = sum(sum(Xlhat .* Xlhat)); 
    ssXl = ssXl / ssXl0; 
    SSXl = [SSXl; ssXl];    
end 
    ssX = (ssXa + ssXb + ssXc + ssXd + ssXe + ssXf + ssXg+ ssXh+ ssXi+ 
ssXj+ssXk+ssXl)/nb_blocks; 
    SSX = [SSX; ssX]; 
    % -------------------------- 
     
    pt = X'*tt / (tt'*tt);  
     
    % Scaling  
    tt = tt*norm(pt); 
    wt = wt*norm(pt); 
    pt = pt/norm(pt); 
     
    Pt=[Pt pt]; 
  
             
    b = u'*tt /(tt'*tt); 
    Y = Y - b*tt*q';    
         
    Tt = [Tt tt]; 
    U = [U u]; 
     
    Ta = [Ta ta]; 
    Tb = [Tb tb]; 
    Tc = [Tc tc]; 
    Td = [Td td]; 
    Te = [Te te]; 
    Tf = [Tf tf]; 
    Tg = [Tg tg]; 
    Th = [Th th]; 
    Ti = [Ti ti]; 
    Tj = [Tj tj]; 
    Tk = [Tk tk]; 
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    Tl = [Tl tl]; 
     
    W = [W wt]; 
     
    Wa = [Wa wa]; 
    Wb = [Wb wb]; 
    Wc = [Wc wc]; 
    Wd = [Wd wd]; 
    We = [We we]; 
    Wf = [Wf wf]; 
    Wg = [Wg wg]; 
    Wh = [Wh wh]; 
    Wi = [Wi wi]; 
    Wj = [Wj wj]; 
    Wk = [Wk wk]; 
    Wl = [Wl wl]; 
     
    Q(:,i) = q; 
    B(i,i) = b; 
     
    % Sum of squares ----------- 
    Yhat = b*tt*q'; 
    ssY0 = sum(sum(Y0 .* Y0)); 
    ssY = sum(sum(Yhat .* Yhat)); 
    ssY = ssY / ssY0; 
    SSY = [SSY; ssY]; 
    % -------------------------- 
     
    error_t = realmax; 
    error_u = realmax; 
       
end 
 
% Make output structures for output; 
Tscores = 
struct('Tt',Tt,'Ta',Ta,'Tb',Tb,'Tc',Tc,'Td',Td,'Te',Te,'Tf',Tf,'Tg',Tg,'Th'
,Th,'Ti',Ti,'Tj',Tj,'Tk',Tk,'Tl',Tl); 
SS = 
struct('SSX',SSX,'SSY',SSY,'SSXa',SSXa,'SSXb',SSXb,'SSXc',SSXc,'SSXd',SSXd,
'SSXe',SSXe,'SSXf',SSXf,'SSXg',SSXg,'SSXh',SSXh,'SSXi',SSXi,'SSXj',SSXj,'SS
Xk',SSXk,'SSXl',SSXl); 
Wloads = 
struct('W',W,'Wa',Wa,'Wb',Wb,'Wc',Wc,'Wd',Wd,'We',We,'Wf',Wf,'Wg',Wg,'Wh',W
h,'Wi',Wi,'Wj',Wj,'Wk',Wk,'Wl',Wl); 
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ANNEXE VI 
 
function [BIP] = fct_BIP_mbPLS_superlevel(SSY,nbblocks,W) 
   
BIP = []; 
  
for i = 1:nbblocks 
        wi = W(i,:); 
        NUM = 0; 
    for j = 1:size(W,2) 
         
        wij = wi(j); 
         
        num = wij.^2 * SSY(j); 
         
        NUM = NUM + num; 
    end 
     
bip = (nbblocks*NUM/sum(SSY)); 
  
    BIP = [BIP; bip];  
end 
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